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ABSTRACT 
 
 
Capillary liquid chromatography coupled to mass spectrometry detection (cLC-MS) 
is an emerging technique for detecting low abundance peptide from microliters of 
sample. Its practicality in monitoring peptides from in vivo microdialysate was limited to 
10 out of more than 200 mammalian neuropeptides due to the slow analysis rate and 
uneven sensitivity for different peptides. The slow speed is not favorable for in vivo study 
which can generate many samples per day, while peptide degradation during storage 
requires immediate measurement after collection. The uneven sensitivity results in high 
limit of detection (LOD) of some neuropeptides, making them undetectable by cLC-MS 
at dialysate concentration.  In this dissertation, cLC-MS’s performance was improved in 
these two aspects.  
The rate limiting step of cLC-MS was the long sample injection/rinsing process due 
to high back pressure using a 25 µm bore column. A method utilized large particle (10 
µm) as LC packing and 75 µm bore column was developed to reduce column back 
pressure and enhance injection/rinsing speed. The method reached 4 min/sample 
throughput compared to previously reported throughput at 20-30 min/sample with similar 
LOD for enkephalins and dynorphin A1-8. This was achieved by rapidly injecting sample 
under 14 µL/min and eluting the peptides slowly under 100 nL/min to maintain nanoESI 
sensitivity. This method was applied for monitoring enkephalins from rat globus pallidus 
(GP) dialysate.  
xvii 
 
To increase peptide detection sensitivity, acetonitrile (ACN) was used as organic 
additive in sample to increase neuropeptide solubility and decrease nonspecific 
adsorption. Adding ACN to optimal concentration improved LOD to low pM range (0.1-
2 pM) from 8 µL sample for all 10 neuropeptides tested in the study. In addition, 
modification of the microdialysis probe using polyethyleneimine (PEI) increased 
sampling recovery by reducing electrostatic interaction between neuropeptides and 
microdialysis catheter. This method was applied for monitoring intact orexins from rat 
arcuate nucleus.  
Application of cLC-MS can be extended to quantifying low abundance proteins using 
a peptide fragment produced from protease digestion (signature peptide method). In 
Chapter 4 a signature peptide method for brain derived neurotrophic factor (BDNF) was 
developed. For BDNF, chymotrypsin produced higher signature peptide signal than 
trypsin digestion, and concentrating the protein prior to denaturation, reduction and 
alkylation was necessary to achieve good signature peptide signal. The method had 5 pM 
LOD for BDNF and neurotrophin-3 (NT-3), and 10 pM LOD for glial cell derived 
neurotrophic factor (GDNF), and can be potentially applied for detecting these 
neurotrophins from in vivo sample.  
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Chapter 1  
 
Introduction 
1.1 Overview of neuropeptides and neuroproteins 
Neuropeptides are peptides produced and released by neurons and are capable of 
exerting signaling effects by binding to neuronal receptors
1
. Neuropeptides are 
synthesized as biologically inactive protein precursors, called prepropeptide, at the 
ribosome of the neuron cell. Prepropeptides undergo proteolytic cleavage to form mature 
neuropeptides, which are packed into large density-core vehicle (LDCVs) and delivered 
to axons and dendrities for release. Neuropeptides are released via exocytosis upon strong 
stimulation in a Ca
2+
 dependent manner. Released neuropeptides can bind to their post-
synaptic neuron receptors, or diffuse into extracellular space, where they can either bind 
to a receptor in neurons distant from the releasing neuron or be deactivated by peptidase. 
Neuropeptides can act as: (1) neurotransmitters that transmit signal between releasing 
neurons and receiving neurons; (2) neuromodulators that modulates small molecule 
neurotransmitter effects; (3) paracrine and autocrine regulators that are involved in cell-
to-cell communication; and (4) hormones that are released into blood stream and exert 
impact on distant organs. Different functions of neuropeptides are depicted in Figure 1.1.  
Neuropeptides constitute the largest and most diverse family of signaling molecules 
in the central nervous system (CNS). Over 70 genes encoding prepropeptides have been 
discovered, and each prepropeptide can produce several active neuropeptides
1
. They are 
involved  in many physiological and pathological processes, such as learning and 
2 
 
memory
2
, pain modulation
3
, sleep regulation
4,5
, appetite control
6
, social interaction
7
, drug 
addiction
4,6
 and depression
8
. Research has been performed to understand neuropeptide 
function from different perspectives,  including: (1) tissue distribution study by locating 
neuropeptide-producing neurons and neuropeptide receptors; (2) quantification from 
tissue extract or body fluids to evaluate disease state and pharmacological treatment; (3) 
in-brain administration for understanding their signaling circuit and potential as drug 
targets; (4) studying animal models lacking or over-expressing certain neuropeptide;  (5) 
in vivo monitoring for direct correlation between their extracellular level and behavior, 
pharmacological treatment and other neurochemical changes in the brain.   
3 
 
 
Figure 1.1 (A) Neuronal release of neuropeptides.  (B) Neuropeptide signaling in the body. 
Neuroproteins are proteins expressed in and associated with the nervous system. 
Unlike neuropeptides, neuroproteins do not act as neurotransmitters; they are usually 
involved in supporting neuronal growth, differentiation and protection. Mutation and 
improper post translational modification of neuroproteins can lead to pathogenesis of 
diseases
9, and cerebral lesion can cause “leaking” of neuroproteins into extracellular fluid, 
eg. cerebrospinal fluid (CSF) and blood
10
. Therefore, their concentration in body fluid 
can serve as marker for disease or brain trauma. For example, τ protein is a neuroprotein 
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that stabilizes microtubules. Hyperphosphorylation of τ leads to microtubule 
disorganization and τ aggregation, resulting in neurodegeneration and diseases such as 
Alzheimer Disease (AD)
11. Studies have shown that elevated phosphorylated τ levels in 
CSF correlate with progression of AD, suggesting its potential as AD biomarker
12
.  
1.2 In vivo neuropeptide and neuroprotein quantification using microdialysis 
sampling  
In vivo measurement of extracellular neuropeptide and neuroprotein release provides 
insights into their dynamics and regulation mechanisms in living subjects; therefore, this 
is an important approach to elucidate their biological functions. Emerging tools for in 
vivo neurochemical monitoring includes in vivo cyclic voltammetry and in vivo sampling 
coupled to highly sensitive analytical techniques.  
In vivo cyclic voltammetry detects neuropeptides by monitoring their oxidation peak 
using a fiber implanted into the brain. It can achieve high spatial resolution and temporal 
resolution; however its application is limited to neuropeptides containing electroactive 
amino acid residues (tyrosine, methionine and cysteine) and has low specificity and poor 
electrode stability. For these reasons it has only been applied in limited number of in vivo 
or living tissue studies
13-15
.  
In vivo sampling has been applied more often because it allows assaying of fractions 
by highly sensitive analytical techniques such as radioimmunoassay (RIA), enzyme 
immunoassay (EIA) and high performance liquid chromatography (LC) with 
electrochemical (EC) or mass spectrometry (MS) detection. Most commonly utilized in 
vivo sampling methods include push-pull perfusion and microdialysis. Push-pull 
perfusion achieves sampling by simultaneously perfusing and withdrawing the perfusion 
5 
 
media through the sampling probe at identical flow rates, carrying neuropeptides in the 
extracellular fluid to the outlet for collection. Similarly, microdialysis also involves 
perfusion media flowing through a probe interior, except that the  “pull” flow is not 
always required because a semipermeable membrane is incorporated at the tip end as 
fluid barrier.  The membrane allows peptides smaller than its molecular weight cut-off 
(MWCO) to diffuse into the probe, driven by the concentration gradient across the 
membrane (Figure 1.2).  
  
Figure 1.2 Scheme of microdialysis probe for sampling molecules from aqueous environment. The 
perfusion fluid is pumped into the probe inlet and flows to the outlet. Molecules smaller than membrane’s 
perfusion fluid 
collection outlet 
membrane 
molecules smaller than membrane MWCO 
molecules bigger than membrane MWCO 
Flow direction 
mass transport  
probe inlet probe outlet 
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MWCO enter the probe through diffusion driven mass transport and are carried  by perfusion media to the 
collection outlet.  
Because of the membrane which sets a physical barrier between the perfusion flow 
and brain tissue, microdialysis has gained favorable attention over push-pull perfusion 
due to lower level of tissue damage and capability of generating cleaner sample
16
. 
Microdialysis is a non-equilibrium sampling technique based on analyte diffusion; 
therefore, the analyte concentration in dialysate is a fraction of the actual extracellular 
concentration. Relative recovery of the probe, defined as the analyte concentration in 
dialysate divided by the actual concentration from the sampling media, is affected by the 
membrane material
17
, active sampling area (membrane length)
17
, dialysis flow rate
18,19
 
and temperature. For proper estimation of extracellular concentration from dialysate 
concentration, the dialysis probe needs to be calibrated. Most commonly employed 
calibration method is in vitro calibration, where the probe samples from a solution with 
known analyte concentration, and analyte concentration in dialysate is measured to 
calculate probe’s in vitro recovery. Other calibration methods were also developed to 
correct the impact of  analyte in vivo dynamics on recovery, these methods include low 
flow  method
20
, no-net-flux method
21
 and retrodialysis
22,23
.  
Microdialysis sampling has been applied to study neuropeptide in vivo signaling and 
its correlation with behavior, disease state and pharmaceutical treatment. One example is 
the in vivo microdialysis of orexin A and melanin-concentrating hormone (MCH) from 
human amygdala. This study revealed that the level of these peptides alters during sleep-
wake cycle and between different emotions, indicating their link to specific emotions and 
state rather than simply arousal
7
.  Using microdialysis coupled to capillary LC-MS, our 
lab demonstrated elevated enkephalin level in rat dorsal neostriatum, and concluded that 
7 
 
these peptides are able to signal consumption of sensory reward
6
. Summary of 
neuropeptides monitored with in vivo microdialysis till 2010 can be found in our previous 
group member’s dissertation24, and Table 1.1 lists a brief update for neuropeptides 
monitored with microdialysis in the last five years.  
With the development of high MWCO membrane, the application of microdialysis 
can extend to in vivo quantification of big peptides and proteins.  Cytokine dynamics and 
their relation to brain injury are perhaps the mostly studied using microdialysis
25-28
. For 
example, a study reported detection of 17 cytokines from human brain dialysate 
following brain tumor resection, and all the cytokines showed gradual decrease in 
concentration, indicating acute brain inflammatory response after surgery
27
. Moreover, 
microdialysis has been utilized in studying the in vivo dynamics of several important 
neuroproteins related to neurodegenerative diseases such as AD.  Protein τ in mouse 
hippocampus interstitial fluid (ISF) was measured using microdialysis, and it was 
revealed that ISF monomeric τ level decreased over age (~200 ng/mL to 72.3 ± 28.0 
ng/mL) and  following the onset of τ aggregation, suggesting the extracellular τ is in 
equilibrium with the toxic τ aggregates29 associated with AD. Microdialysis studies on a 
big neuropeptide β-amyloid (Aβ) also revealed important discovery of  its ISF level 
regulated by synaptic activity
30
 and the correlation to brain’s regional vulnerability to Aβ 
aggregation in AD
31
. In addition, in vivo microdialysis on brain derived neurotrophic 
factor (BDNF) and nerve growth factor (NGF), has shown that intranasal administration 
of carnosic acid caused 3-fold increase in BDNF concentration and 2-fold increase in 
NGF concentration in rat hippocampus, indicating the potential of this drug in treating 
diseases caused by neurotrophin depletion
32
. In vivo microdialysis of α-synuclein (a 
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neuroprotein best known for its association with Parkinson’s disease) and apolipoprotein 
E (ApoE, related to catabolism of lipoprotein constituents, linking to AD due to its 
impact on Aβ metabolism) were also reported33,34. The concentration for α-synuclein 
using in vivo microdialysis was 0.15±0.12 ng/mL in mouse striatum, and ranged from 
0.5-8 ng/mL in human cerebral cortex
34
. The concentration of total exchangeable ApoE 
was 111.2±14.4 ng/mL in mouse hippocampus
33
. These studies show that monitoring 
neuroproteins in the brain of live subjects can lead to unique insight in a variety of 
important topics. 
Table 1.1 In vivo neuropeptide monitoring studies published between 2010 and 2015 
 Peptide MW 
(Da) 
Animal/ Brain 
region 
Quantification 
method 
Dialysate basal 
concentration  
Biological observation 
Neuropeptide- 
S (NPS) 
2210 Rat/ 
Amygdala 
RIA 6.4±1.9 pM
35
 Increased release 
under stress (forced 
swim)
35
 
β-amyloid 
(Aβ)40 
4330 Mouse/ 
hippocampus 
 
ELISA ~13pM
36
 N/A, microdialysis 
method development
36
 
Aβ42 4514 ELISA ~16 pM
36
 N/A, microdialysis 
method development
36
 
Aβx-40 N/A Mouse/ 
hippocampus 
ELISA 148.51 ± 17.93 
pg/mL, ISF 
concentration  
ISF Aβ levels in mice 
predict the degree of 
Aβ aggregation in 
specific brain region
31
 Mouse/ 
striatum 
47.4 ± 11.46 
pg/mL,  ISF 
concentration 
Arginine-
vasopressin 
(AVP) 
1084 Hamster/supra-
chiasmatic 
nucleus (SCN) 
ELISA 34±5 pM
37
 Circadian release both 
under dark-light cycle 
and constant 
darkness
37
 
Rat/paraventricula
r nucleus (PVN) 
cLC-MS 11.1±2.9 pM
19
 Slow and persistent 
response to osmotic 
stress
19
 
Oxytocin 
(OXT) 
1007 Rat/PVN cLC-MS 5.4±1.3 pM
19
 Rapid response to 
osmotic stress
19
 
Methionine-
enkephalin 
573 Rat/GP cLC-MS 14±1 pM
38
 N/A, cLC-MS method 
development 
9 
 
(ME) 64 ± 29 pM
39
 Amphetamine  
increased release, 
suggesting (with other 
data) inhibition on γ-
aminobutyric acid and 
disinhibition on 
dopamine  in  GP to 
sustain locomotion
39
 
Rat/Dorsal 
Neostriatum 
cLC-MS 2.61±0.56 pM
6
 Increased release 
during reward 
consumption
6
 
Leucine-
enkephalin 
(LE) 
556 Rat/ GP cLC-MS 7±1 pM
38
 N/A, cLC-MS method 
development 
15 ± 2 pM
39
 Amphetamine  
increased release, 
suggesting (with other 
data) inhibition on 
GABA and 
disinhibition on DA in  
GP to sustain 
locomotion
39
 
Rat/Dorsal 
Neostriatum 
cLC-MS 2.32±0.30 pM
6
 Increased release 
during reward 
consumption
6
 
kisspeptin-54 
(KP-54) 
5857 Monkey/ 
stalk-median 
eminence (S-ME) 
RIA 61.4±15.3 
fM
40
 
(prepuberty)  
Developmental 
increase in release 
during the process of 
puberty
40
 
gonadotropin-
releasing 
hormone 
(GnRH) 
1183 Monkey/ 
S-ME 
RIA 8.3±3.3 pM
41
 N/A, microdialysis 
method development
41
 
RIA 1.3±0.4 pM 
(prepuberty) 
40
 
Developmental 
increase in release 
during the process of 
puberty
40
 
vasoactive 
intestinal 
peptide (VIP) 
3326 Hamster/ SCN RIA 2.0-60.0 
pg/sample
42
 
Circadian release 
under dark-light cycle, 
release is stimulated 
by photic input and 
inhibited by 
serotonin
42
 
β-endorphin 3466 Rat/central 
amygdala (CeA) 
Solid phase 
RIA 
12900±1000 
pM
43
 
β-endorphin and CRH 
release can be 
stimulated by alcohol,  
CRH release could 
modulate β-endorphin 
release in CeA
43
 
Corticotropin-
releasing 
hormone 
(CRH) 
4758 Rat/CeA Solid phase 
RIA 
663±74 pM
43
 
Rat/dorsolateral 
bed nucleus of the 
striaterminalis 
(dlBNST) 
EIA 95.3±7.3 pM
44
 Formalin evoked pain 
increases CRH 
release
44
 
Orexin A 
 
3561 Rat/ 
hypothalamus, 
amygdala 
RIA 11±2 pM in 
hypothalamus
7
 
6±1 pM in 
amygdala
7
 
Maximal release in 
amygdala during 
positive emotion, 
social interaction and 
10 
 
Human amygdala RIA 11±1 pM
7
 anger, minimal release 
during pain; increased 
release at wake onset 
melanin-
concentrating 
hormone 
(MCH) 
2387 Rat 
hypothalamus, 
amygdala 
RIA 10±3 pM in 
hypothalamus
7
 
10±3 pM in 
amygdala
7
 
Minimal release in 
social interaction and 
pain, increased release 
after eating and at 
sleep onset
7
 Human amygdala RIA 6±1 pM
7
 
Neuromedin B 1132 Rat hippocampus cLC-MS 4 pM
45
 N/A, in vivo cLC-MS 
method development
45
 Neuromedin N 746 11 pM
45
 
 1673 3 pM
45
 
Neurotensin 
 
Rat/ventral 
tegmental area 
(VTA) 
cLC-MS Not reported
46
 Activating lateral 
hypothalamus area 
neurotensin cells 
caused acute and 
transient increase in 
the VTA
46
 
Rat Striatum RIA 144±26 pM
47
 Prolyl oligopeptidase 
is not responsible for 
cleaving neurotensin 
and Sub P in vivo 
47
 
Substance P 
(Sub P) 
1348 Rat Stiratum RIA 11000±800 
pM
47
 
gastric 
releasing 
peptide (GRP) 
2859 Hamster SCN RIA    188±58 pM
37
 Circadian release 
under dark-light cycle, 
reversed rhythmicity at 
constant darkness
37
 
Dynorhpin A1-
8 
(DynA1-8) 
981 Rat/Dorsal 
Neostriatum 
cLC-MS ~4.5 pM
6
 Level remained 
unchanged during 
eating
6
 
Rat/CeA Solid phase 
RIA 
602±60 pM
48
 Alcohol-induced 
increase in release was 
attenuated by CRH 
receptor 2 antagonist
48
 
Orphanin FQ 
(OFQ) 
1809 Rat/ substantia 
nigra reticulate, 
human CSF 
Solid phase 
extraction-RIA 
~100 pM in 
rat, 
~41 pM in 
human CSF
49
 
Parkinsonian toxin 
induced release, 
increased level in CSF 
of Parkinson 
patients—linkage 
between OFQ and 
parkinson’s disease49 
Neuropeptide 
tyrosine 
(NPY) 
4272 Hamster/ 
SCN 
RIA and 
surface 
enhanced laser 
desorption 
ionization 
(SELDI)-TOF 
lower 
detectibility 
~0.39 pM
50
 
Rhythmic release 
under dark-light cycle; 
can be stimulated by 
wheel running, 
intergeniculate leaflet -
mediated release in 
SCN
50
  
 
The biggest challenge in in vivo neuropeptide and protein monitoring using 
microdialysis is the extremely low level (~pM) of neuropeptides and proteins in the 
dialysate, which originates from limited probe recovery and low extracellular level of the 
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peptides. As a result, sampling techniques with higher recovery rate and analytical 
techniques able to quantify sub pM to low nM level of neuropeptide present in 5-100 µL 
dialysate are desired for reliable monitoring and absolute quantification of neuropeptide 
in extracellular space. 
This dissertation focuses on developing analytical methods for in vivo microdialysis 
application for the following neuropeptides and neuroprotein. The peptides are selected 
because of our laboratory and collaborator’s interest in studying their in vivo regulation 
of feeding behavior. 
(1) Enkephalins. Leucine and methionine enkephalin (LE and ME) are two 
pentapeptides from the protein precursor preproenkephalin which contains six copies of 
ME gene and one copy of LE gene
1
. They belong to the opioid peptide family and mainly 
interact with µ and δ opioid receptors51-53. Enkephalins are involved in signaling reward 
consumption (such as eating palatable food)
6
, pain modulation
3
 and locomotors activity
54
. 
They are widely expressed in the brain, and can be measured by microdialysis from 
discrete brain regions such as striatum
6,18
, globus pallidus (GP) 
38,39
 and nucleus 
accumbens
55
 with RIA or LC-MS detection. Enkephalin concentration in dialysate can 
range from ~2 pM to ~130 pM.  
(2) Dynorphin A1-8, 1-17. Dynorphin (A and B) are another type of opioid peptides, they 
derive from pre-prodynorphin and mainly bind to κ opioid receptor51. Dynorphin A 
consists of 17 amino acid residues (DynA1-17), and can undergo further in vivo cleavage 
to form fragments such as DynA1-8, DynA1-13 and DynA2-13 etc. DynA plays role in many 
physiological processes such as pain transmission
56
, stress-induced and proactive 
behavior
57
. Previous study also discovered that infusion of DynA1-8, 1-17 antibody into the 
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brain can cause elevation in feeding threshold
58
. DynA1-17 was measurable in spinal 
perfusate
59
; however no in vivo microdialysis has been performed on it. DynA1-8 is 
studied more with microdialysis, and it can be detected by LC-MS or RIA in different 
brain regions such as CeA
48,60
, striatum
6,18
 and PVN of hypothalamus
19
. DynA1-8 
concentration can range from ~4 pM to ~600 pM in dialysate.  
(3) β-Endorphin. β-Endorphin is an opioid peptide originating from pro-
opiomelanocortin (POMC)
1
 and mainly binds to µ opioid receptor. The full-length 
peptide contains 31 amino acid residues. It can respond to alcohol
60
 and nociceptive 
stimulation
61
, and can stimulate food intake when injected into the brain
62
. β-endorphin 
can be measured by RIA or ELISA using microdialysis from striatum
18
, CeA
43,60
, arcuate 
nucleus of hypothalamus
61
 and spinal cord
63
 with dialysate concentration ranging from 
~35 pM to ~12.9 nM. LC-MS detection of β-Endorphin is achieved by digesting the full-
length peptide to a shorter peptide fragment, which had improved sensitivity
18
.  
(4) α-melanocyte stimulating hormone (α-MSH). α-MSH is a peptide hormone 
cleaved from POMC
1
. It belongs to the melanocortin system in the opioid gene family 
(including adrenocorticotropic hormone and α, β, γ-MSH) and is detected at high 
concentration in discrete neuronal clusters in hypothalamus
64
. In skin and hair α-MSH 
stimulates production of melanin, and in CNS it is involved in feeding behavior
65
 and 
development of addiction
66
. It is suggested that N-acetylated α-MSH (the so-called α-
MSH) and deacetylated α-MSH may have different effect on food intake65. No in vivo 
brain microdialysis has been performed on α-MSH, however it was detected by RIA from 
human dermal microdialysate
67
 and rat hypothalamus push-pull perfusate
68,69
. The 
concentration was ~60 pM and ~30 pM  in dialysate and  perfusate respectively. 
13 
 
(5) Galanin (Gal). Gal is a peptide deriving from prerogalanin, it belongs to the 
galanin gene family and binds to three galanin receptors (GAL-R1, GAL-R2, GAL-R3) 
distributed in PVN, dorsal raphe nucleus, hippocampus and amygdala
70
. It is involved in 
learning and cognition
2
, feeding
71
, cardiovascular regulation
72
 and tumor suppression
73
.  
In vivo microdialysis of galanin was reported in  rat dorsal hippocampal formation
74
 and 
spinal cord
75
 with RIA or HPLC-RIA detection, the dialysate concentration in spinal cord 
was ~7.9 pM.  
(6) Substance P (Sub P). Sub P derives from preprotachykinin A which belongs to the 
kinin and tensin gene family, and binds to neurokinin-1 receptor. Sub P is involved in 
pain/inflammatory response
67
, sleep
76
, emotional stress and psychological disorder
8,76,77
, 
and could also alter feeding behavior through enhancing motor activity when injected to 
ventral tegmental area (VTA)
78
.  Microdialysis of Sub P was reported in periaqueductal 
gray
79
, preoptic anterior hypothalamus
79
, basal ganglia
80
, medial amygdala
77
 and 
trigeminal ganglia
81
. Dialysate concentration measured by RIA ranged from ~4 pM to 
~100 pM. 
(7) Hypocretin/Orexins. Orexin A and orexin B derive from preprohypocretin, and 
they interact with orexin receptors OX1R and OX2R. OX1R is selective for orexin A, and 
OX2R binds nonselectively to both peptides. They are involved in sleep and feeding 
regulation, emotion and energy balance
4
. Orexin in vivo microdialysis was performed 
extensively on orexin A (hypocretin-1) in hypothalamus
5,7,82,83
, basal forebrain
72
, locus 
coeruleus
72
 and amygdala
7
, with dialysate concentration measured by RIA ranging from 
~11-~75 pM. Orexin A in vivo concentration shows circadian fluctuation with elevated 
release during wakefulness and reduced release during sleep. Orexin B has not been 
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measured in in vivo setting yet, and this is possibly due to its fast degradation in the 
body
84
.  
(8) Nociceptin/Orphanin FQ (OFQ). OFQ derives from prepronociceptin and belongs 
to the orphanin gene family. It binds opioid receptor like-1 receptor and plays roles in 
modulating nociception
85
, feeding regulation and anxiety
86
. Microdialysis on OFQ has 
been performed  in  rat hippocampus
87
, thalamus
87
 and substantia nigra reticulata
49
 and 
concentration in dialysate as measured by RIA (or solid phase extraction, SPE coupled to 
RIA) ranged from ~60 pM to ~149 pM.  
(9) Cholecystokinin tetrapeptide (CCK-4). CCK-4 is a tetrapeptide fragment of 
cholecystokinin (CCK) from the preproCCK, which belongs to the CCK/gastrin gene 
family. CCK-4 is involved in panic induction
88
, memory deterioration and anxiety
89
. No 
in vivo microdialysis has been performed to detect this peptide, although other forms of 
CCK have been measured in vivo from rat anterior cingulated cortex
90
 and rostral 
ventromedial medulla
91
. 
(10) Brain derived neurotrophic factor (BDNF). BDNF is a neuroprotein in the 
neurotrophin family. It plays critical role in neuron cell survival, differentiation and 
neuronal plasticity
92
. Its concentration in body fluid and tissue has correlation with AD93-95 
and several mental disorders such as major depression and bipolar disorder96-99.  BDNF can 
also be measured in vivo. In a study measuring its release from supraoptic nucleus using 
push-pull perfusion, the basal level was below limit of detection using a commercial ELISA 
kit, and the level under osmotic stress was approximately 40 pg  (3 fmol) per 15 min 
fraction100. Another in vivo microdialysis study reported its endogenous level in rat 
hippocampal region to be 207 ng/ml (15 pM)32. 
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1.3 Recent improvement in in vivo neuropeptide/protein sampling technique 
Relative recovery rates for neuropeptides and proteins typically range between <1% 
to 20%
18,19
  depending on the analyte, probe membrane material, probe construction and 
flow rate used. Reasons for the low recovery of neuropeptides and neuroproteins include 
their low diffusion coefficient, non-specific adsorption loss and fluid loss across the 
dialysis membrane. Table 1.2 summarizes recent studies on improving the recovery of 
microdialysis-based sampling techniques focusing on solving the three problems. 
1.3.1 Reducing non-specific adsorption by probe/tubing modification 
Peptides and proteins are observed to bind to surface and microdialysis probes at µM 
level
101,102
. The adsorption can be described by Langmuir isotherm
102
, meaning that 
adsorption loss can become more severe when being sampled at physiologically relevant 
concentration (pM to nM). Modification on the microdialysis tubing
5,82
 and probe
103
 to 
block active adsorption sites has been investigated for reducing adsorption loss. 
Particularly, a commercially available PEO98-PPO67-PEO98 triblock copolymer (Pluronic F-
127) was utilized to reduce protein adsorption loss when sampling from human CSF. This 
polymer self-assembles onto hydrophobic microdialysis membrane and tubing through 
interaction with the hydrophobic moiety polypropylene oxide (PPO), leaving hydrophilic 
polyethylene oxide (PEO) chain to form a water-swelling, protein repelling layer on the 
surface.  The modification increased average protein recovery of a 10 mm probe from 
23.9% to 32.1% when sampling from human CSF
103
.  
Recent work in preparing fouling-resistant membranes for hemodialysis
104-108
 
suggests a route to producing low binding materials that can potentially be utilized in 
neuropeptide/protein microdialysis sampling. The polyethyleneimine (PEI) modification 
method on AN69 membrane is of particular interest to our laboratory. AN69 is a 
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hydrophilic polyacrylonitrile (PAN) membrane with embedded sulfonate group that has 
previously been shown to have excellent relative recovery for several small 
neuropeptides (LE, ME, DynA1-8, OXT, AVP)
6,19
. Modifying the membrane by physical 
adsorption of a hydrophilic, polycationic PEI may offer a convenient way to reduce 
electrostatic interaction and improve recovery of bigger, positively charged neuropeptides. 
Evaluation of recovery change after PEI modification will be discussed in detail in 
Chapter 3.  
Another simple alternative to reduce non-specific adsorption loss of neuropeptide and 
neuroprotein is to add a non-analyte protein (usually bovine serum albumin, BSA or 
human serum albumin, HSA) into the perfusion media to block the adsorption site. The 
protein additive also helps reduce fluid loss due to osmotic pressure difference (discussed 
in the next section), therefore has been widely utilized as a standard method in 
peptide/protein sampling
75,87,109-111
. Although being effective, the concentration of serum 
albumin (0.1-4% w/v) in perfusion media is much higher than the neuropeptide/protein 
concentration. Therefore additional sample clean-up may be required when quantifying 
dialysate using highly sensitive cLC-MS, because blocking protein can also be 
preconcentrated on the capillary column and interfere with analyte neuropeptide/protein 
retention and detection. In addition, leaking of blocking protein into the brain is possible 
(see below).  
1.3.2 Reducing fluid loss across microdialysis membrane 
Microdialysis for small molecules is typically performed using membranes with 
MWCO of 6-15 kDa. In contrast, the MWCO of microdialysis membrane for 
neuropeptide and protein sampling is usually between 20-1000 kDa due to their bigger 
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size compared to small molecule neurotransmitters. The higher MWCO membrane 
contains bigger through pores
112
, which are more prone to leakage due to hydrostatic 
pressure and osmotic pressure of the perfusion media. Leakage is readily observable 
when using a 100 kDa MWCO membrane
103
; it causes bulk fluid movement from the 
microdialysis probe into the sampling space, resulting in both concentration and sample 
volume loss. Instead of solely pressurizing the perfusion media, microdialysis in “push-
pull” format is proven to effectively reduce pressure difference across the membrane and 
achieved both ~100% fluid recovery and increased neuropeptide/protein recovery
36,113,114
.  
Another approach to reduce fluid loss is to add a macromolecule osmotic reagent 
(serum albumin or dextran) into the perfusion media to balance the osmotic pressure 
difference between perfusion media and the protein-containing extracellular fluid. Some 
studies have suggested that using the osmotic reagent alone can achieve ~100% fluid 
recovery and good protein recovery
115
; although it was recommended to always use push-
pull microdialysis when sampling big neuropeptides/proteins. In addition to potential 
interference with subsequent analyte detection, concern associated with osmotic reagent 
is its potential to leak into sampling space when a probe with MWCO larger than the 
molecular weight of osmotic reagent is used. For example, BSA (MW = 66 kDa) may 
leak into the brain when flowing through a 100 kDa or higher MWCO probe. Such 
leakage could trigger undesired biological response that interferes with the ongoing in 
vivo study. Evaluation of possible leakage
116
 was carried out based on the inflammatory 
response when microdialyzing in rat spinal horn with BSA, rat serum albumin (RSA), 
Dextran 70 and Dextran 500 as perfusion media supplement using a 100 kDa MWCO 
probe. Significant inflammation was observed with the use of Dextran 70, indicating that 
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it is leaking through the probe and should be eliminated in future in vivo microdialysis 
experiments.   
1.3.3 Modified sampling technique to overcome limited peptide/protein diffusion 
The non-equilibrium sampling of microdialysis has determined that molecules with 
larger diffusion coefficient have higher relative recovery, making this technique not as 
favorable when sampling bigger neuropeptides/proteins whose diffusion coefficient is 
low. To overcome this barrier, different approaches improving neuropeptide/protein 
delivery into the probe have been reported, including microdialysis-ultrafiltration 
sampling and affinity enhanced sampling.   
Microdialysis-ultrafiltration sampling utilizes a push-pull microdialysis set up with 
the “pull” flow rate greater than the “push” flow rate to generate bulk fluid movement 
into the sampling probe that facilitates the recovery of neuropeptides/proteins. Studies 
have shown 50%-100% recovery achieved for peptides and proteins
113,117,118
, and this 
technique is proven to be useful for in vivo studies where reduction of ~10-100 µL of 
extracellular fluid  does not cause drainage or disturbance of extracellular fluid (eg. in 
human mucosa, blood etc)
117
.  
Affinity enhanced sampling methods improve analyte recovery by including in the 
perfusion media an affinity agent (cyclodextrin
119
, antibody
120
, conjugated heparin
121
) 
that binds selectively with high affinity to target analyte to increase concentration 
gradient and facilitate mass transport across the membrane. The affinity agent can be 
either in free solution or immobilized on microspheres. Antibody showed higher recovery 
over other agents
122-124
 . Antibody immobilized microspheres also provides easier 
interface with multiplexed detection methods such as LC-MS
124
 or flow cytometry
123
. 
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Challenges in the wide application of antibody immobilized microsphere, in addition to 
its lengthy preparation and bead saturation issue, are bead settling and tubing clogging, 
which was still observed in a recent study
124
 where nanospheres were utilized as intentin 
to solve these problems. A separate study utilized air-segmented flow plug to effectively 
prevented microsphere settling and clogging, and showed 10-fold improvement in 
GnRH’s in vitro recovery125.  However the safety and effectiveness of this method was 
not validated for in vivo sampling. 
Table 1.2 Solutions to improve microdialysis sampling and examples 
Targeted cause Solution Reported recovery (or improvement) 
Non-specific 
adsorption  
 
Using siliconized tubing Orexin A recovery: 0.8±0.3% 
5
 at 0.3 µL /min 
Pluronic F-127 adsorption  to 
create hydrophilic surface 
transferrin recovery:  59.7 %  
β-hemoglobin recovery: 61.5 % 103 at 0.3 µL /min 
 
Polysulfone/phospholipid 
blend membrane 
Reduced albumin, 
γ-globulin and fibrinogen adsorption visualized by 
immnogold-scanning electron microscopy
104
 
Modifying AN69ST 
membrane by heparin 
adsorption 
Reduced coagulation due to reduced protein 
adsorption
105
 
New membrane material using 
polyethersulfone blended with 
2-hydroxyethl methacrylate 
and acrylic acid  
76% less BSA adsorption and 80% less bovine 
serum fibrinogen adsorption compared to 
polyethersulfone membrane
106
 
PEI physical adsorption onto 
PAN membrane 
Reduced adsorption of high molecular weight 
kininogen 
108
 
Adding blocking protein 5.5±0.2% for somatostatin (SMT) at 5 µL/min 
109
  
6.2 ± 0.3% for OFQ at 2 µL/min
87
 
2.0±0.13%–2.6±0.27% for CCK-8 at 3.5 µL/min110 
1.4%-1.5% for Gal at 3.5 µL/min
75
 
6.6±1.3% for Sub P at 3 µL/min
111
 
Fluid loss “Push-pull” microdialysis  ~15%-28% for cytochrome c, human serum albumin,  
ribonuclease A, lysozyme and α-lactalbumin 113 
~13% for Aβ40, ~16% for interleukin (IL)-6
36
 
IL-1β:27.8±4.1%; IL-6:45.2±8.4%; NGF: 22.2±7.9% 
114
 
Macromolecule as osmotic 
reagent 
~100% fluid recovery using 10% BSA, IL-1β 
recovery ~2.7%
115
 
 94% and 100% fluid recovery with Dextran 60 and 
Albumin
126
  
~100% fluid recovery with Dextran 250
103
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Diffusion 
limitation 
Affinity enhanced sampling 64.8 ± 11.7% for chemokine ligand (CCL)-2
120
 
~70% for interferon (IFN)-γ and ~35% for tumor 
necrosis factor (TNF) -α121 
60.4 ± 5.8% for TNF-α;  25.8 ± 2.3% for IFN-γ; 4.9 
± 0.1% for IL-5; 78.8 ± 8.0% for IL-4; 19.8 ± 2.5% 
for IL-2
123
 
55.2 ±5.29% for fibril-associated protein (FLP)-1, 
87.3±5.09% for FLP-2, 92.1±3.45% for Sub P, 
82.9±5.25% for SMT
124
 
Microdialysis-ultrafiltration 100% for LE, vasopressin and BSA
118
 
~50%-~90% for cytochrome c, human serum 
albumin,  ribonuclease A, lysozyme and α-
lactalbumin
113
 
52 ± 0.4%, 46 ± 1% and 38 ± 6% for myoglobin, 
soybean trypsin inhibitor and carbonic anhydrase
117
 
1.4 Analytical methods for detecting low abundance intact peptide/protein 
The low neuropeptide/protein concentration (Table 1.1) and very limited volume of 
dialysate sample (1-100 µL) require analytical method with good mass sensitivity. Most 
neuropeptide/protein quantifications rely on immunoassays, such as RIA and ELISA, 
which detect analyte based on the molecular recognition and binding between antigen and 
antibody. These techniques can achieve excellent mass LOD (<1-100 amol) with wide 
selection of commercially available kits, therefore require minimal method development. 
However, the entire detection process can take from 6 hours to 2 days. Although 
throughput can be enhanced by assaying in 96-well and 384-well format, the long 
analysis turnover can be problematic due to the degradation issue of neuropeptides.   
Single-analyte detection is another limitation of these methods, meaning extra sample 
volume is needed when monitoring more than one neuropeptide/protein, leading to 
elongated fraction collection between time points and subsequently reduced temporal 
resolution.  Moreover, these techniques suffer from cross reactivity issue because they do 
not detect peptides and proteins based on their amino acid sequence; a non-analyte 
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peptide/protein with similar binding affinity to the antibody can also generate signal, 
leading to false positive.  
Numerous studies have been conducted in improving the speed and multi-analyte 
capacity of immunoassays for peptides/proteins. A commercialized swirling micro-
channel plate was utilized to enhance mass transfer in ELISA’s incubation step, reducing 
detection time to ~2 h and sample/reagent consumption to 5 µL while maintaining 
ultrahigh sensitivity of ELISA (LOD= 13 fM for human IL-4)
127
.  Microarrays, 
microbeads, nanoparticles were also popular media for realizing fast and multiplexed 
detection of neuropeptides/proteins, with limit of detection as low as 83 aM
128-132
, and 
platform for simultaneous detection of up to 100 protein/peptides were already 
commercialized
133
. In addition, microfluidic platform such as lateral flow integrated 
blood barcode chip (LF-IBBC)
134
 and centrifugal microfluidics
135
 were applied to 
immunoassays to achieve accelerated and multiplexed protein detection. The assay time 
can be as short as 20-50 min with low pM LOD  from 200 nL of sample
136
. Although 
supreme performance, in terms of sensitivity, throughput, speed and multi-analyte 
detection can be achieved by immunoassays, they still suffer from potential cross 
reactivity issue when structurally similar interference peptides/proteins are present in the 
sample, which may result in false positive in the measurement. 
LC-EC or LC-MS are promising alternatives to immunoassays in detecting 
neuropeptides, due to their higher specificity and sensitivity to small peptides, especially 
peptides with MW < 2000 Da. In these methods, 4-10 µL of peptide-containing sample is 
injected onto a column packed with reverse phase separation media and retained on the 
head of the column. After rinsing the column with weak mobile phase (aqueous solution) 
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which removes unretained matrix components such as salt, the retained peptides are 
eluted by strong mobile phase (organic solvent such as methanol and acetonitrile) and 
detected by highly sensitive EC or MS. EC detects peptides containing electroactive 
residues such as tyrosine, cysteine and methionine. Derivatization procedure can be used 
for peptides not containing these residues
137,138
. On the other hand, the development of 
MS techniques, such as soft ionization (electrospray ionization, ESI and matrix assisted 
laser induced desorption ionization, MALDI) technique, advanced mass analyzer (ion 
trap, triple quadrupole) has enabled highly sensitive, sequence-specific detection of 
neuropeptides using multistage MS (MS
n
). In addition, the application of a capillary LC 
(cLC) column (Figure 1.3), capable of preconcentrating microliters of peptide solution 
into 20-50 nL elution band, can further increase the sensitivity of LC-MS based detection. 
Combining preconcentration, LC separation with the sensitivity and specificity of MS 
detection, cLC-MS can achieve simultaneous monitoring of several neuropeptides with 
mass LOD as low as 2 amol and concentration LOD as low as 0.5 pM
18
. It has been 
successfully applied to monitor 10 neuropeptides from the brain, including Angiotensin 
IV (Ang IV)
139
, ME
6,18,19,38,39,137,140,141
, LE
6,18,38,39,140,141
, DynA1-8
18
, neurotensin
45,46,142
, β-
endorphin
18
, AVP
19
, OXT
19
, neuromedin N
45
 and neuromedin B
45
. 
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Figure 1.3 Scheme of preconcentration and capillary LC-ESI-MS analysis of neuropeptide. 
Limitations do exist in the application of cLC-MS in routine in vivo 
neuropeptide/protein quantification. The highest sensitivity is achieved with the smallest 
bore column (25 µm I.D.), because it provides largest preconcentration ratio and lowest 
flow rate for highest nano-ESI signal. However the small bore columns are also subject to 
elongated analysis time due to slow sample injection and limited column stability (i.e. 
usually suitable for 20-40 injections in our laboratory), making cLC-MS impractical 
when analyzing large number of samples (eg. in vivo neurochemical monitoring). 
Improvement on cLC-MS analysis speed and column stability is discussed in chapter 2.  
In addition, only 10 mammalian neuropeptides have been monitored in vivo using 
cLC-MS. Most of them have MW < 2000 Da, indicating the sensitivity might not be 
adequate enough for monitoring intact larger neuropeptides with molecular weight >2000 
Da. In fact, a previous study has reported that β-endorphin (3466 Da) had an LOD of 5 
Sample injection 
Column rinsing 
Peptide elution and detection 
 time m/z 
Salt 
Peptides 
MS 
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nM when detected intact, which was far too high for in vivo work. A signature peptide 
method (discussed below) was required to quantify this peptide from in vivo dialyate
18
.  
Table 1.3 summarizes developments in LC-MS for trace level detection of intact 
neuropeptides since 2010. It shows a general trend in improving peptide detection 
sensitivity and preventing adsorption loss by using either organic additive
143,144
 or 
protein-containing matrix
145-147
 for higher sensitivity. With these improvements, low-to-
high pM LOD for several neuropeptides larger than 2000 Da was achieved using large 
bore capillary column (300 µm I.D.)
144
 and regular-size LC columns (1-2.1 mm I.D.). 
These peptides include orexin A (3561 Da)
144
, orexin B (2936 Da)
144
, parathyroid 
hormone1-34 (PTH, 4118 Da)
144
, salmon calcitonin  (3432 Da)
148
, Apelin-36 (4196 Da)
149
, 
Aβ38 (4132 Da)
146,147
, Aβ40 (4330 Da)
146,147 
 and  Aβ42  (4514 Da)
145-147
. Although the 
mass LOD or lower limit of quantification (LLOQ) were still at low-to-mid fmol range, it 
could potentially be improved by using cLC column which is capable of preconcentrating 
peptides to smaller elution band.  
Table 1.3 Improvement in LC-MS quantification of trace level neuropeptide from biological sample 
Method highlight MS  Sample 
matrix 
LOD (converted to mole unless 
specified) 
Highly sensitive cLC-MS
3
 
for in vivo monitoring of 
AVP and OXT  
LTQ XL linear ion 
trap 
(Thermo) 
In vivo 
dialysate 
5 amol for AVP and OXT
19
 
cLC-MS
3
 with large 
particulate phase to reduced 
injection backpressure, 
increasing analysis speed to 
4 min/sample for in vivo 
monitoring of ME and LE 
LCQ Deca XP Plus 
quadrupole ion trap 
(Thermo) 
In vivo 
dialysate 
15 amol for LE and ME 
50 amol for DynA1-8
38
  
nanoUPLC-MS
2
 with 
organic additive to reduce 
adsorption, optimized 
dilution  solvent in standard 
preparation  
Quattro Premier 
triple quadrupole 
(Micromass-Waters) 
In vivo 
dialysate 
LLOQ: 200 amol for neurotensin   
and neuromedin N,600 amol for 
neurmomedin  B 
133
 
Xevo TQ-S triple 
quadrupole  
(Waters) 
In vivo 
dialysate 
LLOQ: 2.5 amol for neurotensin and 
neuromedin N,15 amol for 
neurmomedin  B
45
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LC-MS
2
 with optimized 
gradient to reduce matrix 
suppression  
TSQ EMR quantum 
quadrupole ion trap 
(Thermo-Finnigan) 
Rat 
plasma 
80 pM (200 µL rat plasma extracted 
to 100 µL,50 µL injected, 
corresponding to 8 fmol) for KP-
10
150
 
Solid phase extraction 
(SPE)- UPLC-MS
2
 for 
direct detection of intact 
large peptide 
Xevo TQ-S triple 
quadrupole  
(Waters) 
Human 
plasma 
LLOQ: 3 pM (500 µL  plasma 
extracted to 150 µL,20 µL injected, 
corresponding to 200 amol) for 
salmon calcitonin
148
   
Reduced nonspecific 
adsorption with ACN 
addition; elution from trap 
column w/ 10 ×online 
dilution to refocus peptide 
to a cLC column 
LTQ linear ion trap 
(Thermo) 
 
Human 
plasma 
50 pM (37.5 fmol) for α-MSH, 
GnRH, Sub P and OXT 
250 pM (187.5 fmol) for brain 
natriuretic peptide (BNP), C-Peptide 
, PTH, orexin B 
750 pM (562.5 fmol) for orexin A
144
 
High-throughput SPE 
coupled to 2D-LC-MS
2
 to 
reduce matrix suppression 
API 4000 tandem 
quadrupole 
(Applied 
Biosystems) 
Human 
plasma,  
Rat 
plasma 
1 pM (1400 µL human plasma 
extracted to 100 µL,15 µL injected, 
corresponding to 210 amol) 
50 pM (200 µL rat plasma extracted 
to 100 µL, 15 µL injected 
corresponding to 1.5 fmol) both for 
OXT
151
 
Electromembrane extraction 
coupled to LC- MS
2 
for fast 
sample preparation and 
sensitive detection 
triple quadrupole 
(unspecified model) 
(Thermo) 
Human 
plasma 
57 pM for Ang II, 43 pM for LE, 39 
pM for endomorphin 1 (2 mL human 
plasma extracted to 60 µL acceptor 
solution, 50 µL injected )
152
 
Weak cation exchange 
(WCX) extraction using 
magnetic microbeads 
coupled to LC- MS
2
 
TSQ Quantum Ultra 
triple quadrupole 
(Thermo) 
Human 
plasma 
7 pM, 14 pM, 9 pM, 12 pM for 
Apelin-12, -p13, -17, -36 (500 µL 
human plasma extracted to 50 µL, 30 
µL injected corresponding to 2.1 
fmol, 4.2 fmol, 2.7 fmol, 3.6 fmol)
149
  
SPE - UPLC- MS
2
, 
optimized MS
2 
setting for 
neuropeptide detection 
Xevo TQ-S triple 
quadrupole  
(Waters) 
sea 
lamprey 
brain 
tissue, 
plasma 
8 pM, 6 pM, 24 pM for GnRH-I,-II,-
III (1000 µL tissue supernatant 
extracted to 100 µL, 10 µL injected, 
corresponding to 800 amol, 600 
amol, 2.4 fmol)
153
 
Development of surrogate 
matrix to mimic CSF and 
minimize adsorption, SPE 
of denatured sample 
followed by 2D-UPLC-MS
2 
with stable isotopically 
labeled (SIL) internal 
standard to minimize matrix 
effect 
API 5000 triple 
quadrupole 
(ABSciex) 
4 mg/mL 
BSA in 
aCSF 
LLOQ: 11 pM (200 µL sample 
extracted to 100 µL, 50 µL injected, 
corresponding to 1.1 fmol) for 
Aβ42
145
  
Use of SIL internal standard 
for reverse calibration to 
eliminate matrix effect, SPE 
of denatured sample 
coupled to LC-MS
2
 for 
simultaneous quantification 
of Aβ38, Aβ40, Aβ42  
TSQ Vantage triple 
quadrupole 
(Thermo) 
Human 
CSF 
LLOQ: 61 pM, 14 pM, 13 pM (200 
µL sample extracted to 25 µL, 20 µL 
injected corresponding to 9.8 fmol, 
2.2 fmol, 2.1 fmol) for Aβ38, Aβ40, 
Aβ42
147
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Development of surrogate 
matrix to mimic CSF and 
minimize adsorption, SPE 
of denatured sample 
followed by UPLC-MS
2
 
with SIL to minimize matrix 
effect 
Xevo TQ triple 
quadrupole  
(Waters) 
aCSF w/ 
5% rat 
plasma 
LLOQ: <0.1 ng/ml (200 µL sample 
extracted to 75 µL, 10 µL injected) 
for Aβ38, Aβ40, Aβ42
146
 
 
In addition to adsorption loss, bigger neuropeptides and proteins may suffer from 
compromised sensitivity due to multiple charge state that disperses signal in ESI-MS and 
poor ion transmission at high m/z. Recent advances in quadrupole-time of flight (Q-TOF), 
orbitrap and Fourier transform ion cyclotron resonance (FT-ICR) mass analyzer have 
allowed detection of intact protein approaching one mega Daltons with modification in 
source design, source pressure, electronics and detectors
154-157
. Zeptomole LOD for small 
proteins (8-20 kDa)
157
 and low amol LOD of intact IgG (146 kDa)
154
 have been achieved 
when directly infusing protein standard into MS. However, such modifications are 
usually built-in-house and are not readily available on commercial MS, and they have no 
demonstrated application in real biological samples. Improvement in analytical methods 
based on other type of MS also enabled highly sensitive protein detection. Element 
tagged immunoassay and element tagged affinity labeling strategy labels protein with 
metal ions for inductively coupled plasma mass spectrometry (ICPMS) detection, and can 
be coupled to various separation techniques such as HPLC and CE to achieve sub fmol to 
low amol detection of proteins
158,159
. Advantages of this method include high sensitivity, 
wide dynamic range, ease of generating internal standard and signal independency of 
chemical species; drawbacks are lack of sequence-specific information (therefore highly 
specific antibody or high resolution separation must be used) and labeling efficiency 
issue at low protein concentration. MALDI is another option to circumvent the multiple 
charge issue encountered using ESI. However it is also associated with poor 
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quantification due to heterogeneous crystallization of sample across the spot and 
mismatch between sample spot size (1-2 mm) and size of the laser spot (~200 µm). 
Improvement of MALDI target plate design
160-163
, surface chemistry
164,165
 and liquid 
dispensing techniques
160,166
 enabled  confinement of  protein sample into ~100-500 µm 
dry spot, minimizing ionization heterogeneity across sample spot and achieving low amol 
detection of protein
160
. A recent in vivo study utilized a variation of MALDI, called 
surface enhanced laser desorption ionization (SELDI) to detect NPY. This method used 
antiNPY coated target plate for peptide capture and enrichment, resulting in lower NPY 
detectability of 0.1 pg from 60 µL microdialysate
50
.  
1.5 Signature peptide method for low abundance protein quantification 
Currently the most popular non-immunological method for low abundance protein 
quantification is signature peptide method. This method digests large protein into 
fragment peptides that serve as analytical surrogates of the protein (Figure 1.4). The most 
widely used protease in signature peptide method is trypsin, because it has high activity 
and specificity at the carboxyl side of lysine and arginine. By converting protein into 
signature peptides, this method in theory possesses all the advantages of (capillary)LC-
MS including specificity, sensitivity and multi-analyte capacity. Also, absolute 
quantification (AQUA) can be achieved by introducing a synthesized, stable isotopically 
labeled (SIL) signature peptide during the digestion process
167
. In reality, reaching 
similar performance as small peptide detection can be challenging for several reasons.  
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Figure 1.4 Scheme for protein digestion and signature peptide method  
First (and fundamentally), the selected signature peptide must properly represent the 
target protein. Sequence similarity search should always be performed in database such 
as the basic logical alignment search tool (BLAST) to confirm the uniqueness of 
signature peptide to target protein
168
. Also it is advised that signature peptide selection 
should avoid sequence containing sites with possible posttranslational modifications (eg. 
methionine, cysteine and tryptophan)
169
 , possible miscleavage sites (KK, RR, RP, KP)
170
, 
and the signature peptide should be monitored for 3 daughter ion transitions in MS
2
 mode 
to ensure specificity
171
.  
Second (and more important in the practical side), even for optimally selected 
signature peptide, its production and detection from low abundance protein in a complex 
biological sample can be difficult: the digestion may not reach completeness to fully 
release signature peptide for protease resistant protein presenting at trace level, and the 
sample matrix can further interfere with signature peptide yield and detection
148,172
. 
Impact of protease
173
, protease format
174-176
 and denaturing conditions
177-179
 have been 
studied for improving digestion efficiency, revealing that these factors all affect 
Intact protein 
heat, organic solvent, 
surfactant, chaotrophic 
reagent 
+ Dithiothreitol  or 
tris(2-carboxyethyl)phosphine 
+ Iodoacetamide + Protease (trypsin) 
LC-MS 
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completeness of digestion.  However, the impact of these parameters on signature peptide 
production at trace concentration is not frequently assessed when developing signature 
peptide methods. In chapter 4 of this dissertation, the impact of these factors will be 
studied on signature peptide production from BDNF at low concentration as a proof of 
concept study for highly sensitive signature peptide method for this protein.  
Another key factor in successful signature peptide methods is use of purification and 
concentration strategies. When applied for complex samples such as whole blood, plasma, 
tissue homogenate and CSF
168
, sample fractionation both before and after digestion may 
be required.  Protein purification prior to digestion can be achieved  based on its intrinsic 
properties including size, isoelectric point and hydrophobicity, with techniques such as 
solid phase extraction (SPE)
180
, size exclusion chromatography (SEC)
181
, 
ultracentrifugation (UC)
182
 and organic precipitation
170
. Immunopurification techniques 
such as immunodepletion which removes abundant protein from sample
183
, or 
immunocapture which selectively concentrates target protein
184
, have also been applied 
for protein purification. Purification of signature peptides can be achieved by similar 
approaches. Particularly, stable isotope standards and capture by anti-peptide antibodies 
(SISCAPA) was developed to capture signature peptide along with its SIL internal 
standards using anti-peptide antibody for simultaneous sensitivity enhancement and 
absolute quantification
169
.  
For application in low abundance protein quantification, immunocapture usually 
gives higher sensitivity due to the high binding affinity of antibodies towards target 
protein/signature peptides. For example, an approach utilizing double immunoaffinity 
enrichment of target protein and online immunoaffinity chromatography-RPLC-MS
2
 of 
30 
 
signature peptide gave LLOQ at 0.05 pM for IL-21 from 500 µL plasma (~50% 
injected)
185
, equaling to 12.5 amol mass LLOQ. In another study, immunoprecipitation in 
96-well ELISA format (IPE) followed by microwave-assisted protein digestion have 
shown LLOQ at 17 pM for N-terminal prohormone of brain natriuretic peptide from 50 
µL serum (mass LLOQ 850 amol)
186
. Measurement of τ protein from CSF has also been 
realized by signature peptide method. This study employed immunoaffinity purification 
of τ protein along with a recombinant, SIL protein that served as internal standard to 
account for variability of the entire sample preparation and analysis process. The limit of 
quantification (LOQ) was 0.25 pM from 150 µL CSF and the method was able to detect 
significantly higher τ concentration in AD CSF187. Despite its high sensitivity, one 
potential drawback of immunocapture method is the availability of antibody for proteins 
and (especially) signature peptides, and the development of such antibody can take long 
time.  
Non-immunocapture methods have also been explored for low abundance protein 
quantification. A method utilizing a single extraction step with acidic isopropanol to 
remove endogenous plasma protein yielded LLOQ at 190 pM for a protein drug from 50 
µL plasma
170
. Another method using strong cation exchange (SCX) fractionation of 
tryptic digest prior to LC injection improved sensitivity by reducing matrix effect, and 
LOQ of 1-10 ng/mL (100-200 amol injected on column) was achieved for proteins spiked 
into immunodepleted plasma
183
. With recent advances in high resolution separation, an 
“antibody-free” (although immunodepletion was still used) signature peptide method was 
reported to have LOD at low pM range, using high-pressure, high-resolution separations 
coupled with intelligent selection and multiplexing (PRISM)
188
. In this approach, the 
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digested protein was spiked with SIL signature peptide internal standard for locating the 
signature peptide-containing fraction in the first dimension LC using a split flow design, 
and only the signature-peptide-containing fractions were injected to the second dimension 
LC column. This method achieved <50 pg/mL LOD for four proteins (for prostate-
specific antigen 50 pg/mL=1.7 pM), owing to the improvement in separation and 
subsequently reduced matrix interference. This method was further evaluated with non-
immunodepleted serum, and the LOQ was in low ng/mL range
189
. 
1.6 Dissertation overview 
The work presented in this dissertation focuses on improving the analytical 
practicality and sensitivity of cLC-MS in neuropeptide/protein detection, with application 
in in vivo monitoring of neuropeptide enkephalins and orexins.  
Chapter 2 studies analytical speed enhancement of cLC-MS by increasing the sample 
loading speed. The speed increase is achieved by reducing column’s backpressure, 
enabling higher injection flow rate and shorter sample injection, which is the rate limiting 
step for cLC-MS analysis of neuropeptides. In this chapter, capacity of 75 μm I.D. 
capillary column packed with 10 μm reversed phase particles is evaluated for increasing 
throughput in cLC-MS
n
 based neuropeptide measurement. Coupling a high injection flow 
rate for fast sample loading/desalting with a low elution flow rate to maintain nano-ESI 
sensitivity, this column reduces analysis time from ~20-30 min to 3.8 min for 5 μL 
sample, with 3 pM  LOD for enkephalins and 10 pM LOD for DynA1-8. The use of 
isotopically labeled internal standard lowers peptide signal variation to less than 5%. This 
method is validated for in vivo detection of LE and ME with microdialysate collected 
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from rat GP, and has been published in Journal of the American Society for Mass 
Spectrometry (2013, volume 24, page 1700-1709) . 
Chapter 3 focuses on improving in vivo detection of neuropeptides by both increasing 
cLC-MS’s sensitivity and recovery of microdialysis sampling. Enhancement in sensitivity 
is achieved by adding ACN as organic modifier to peptide sample that reduces pre-
injection loss caused by non-specific adsorption, reducing LOD for 10 tested 
neuropeptides to 0.1-2 pM from 8 µL sample. Improvement in microdialysis recovery is 
realized by modifying the hydrophilic, negatively charged AN69 membrane and fused 
silica tubing by polycationic PEI. The modification shows significant improvement in 
recovery for 7 positively charged neuropeptides, and is likely due to reduced electrostatic 
interaction. This method is then validated for in vivo monitoring of orexins from rat 
arcuate nucleus, and low pM level of orexins are quantified from the dialysate. This 
chapter has been prepared for publication in Analytical Chemistry. 
Chapter 4 will discuss about the development of a signature peptide method for 
BDNF. BDNF has high structural stability and does not generate good tryptic peptide 
signal; while chymotrypsin is found to produce higher signature peptide signal.  
Concentrating the protein before denaturation and using immobilized chymotrypsin also 
helps increase the production of signature peptide. Using BDNF’s optimized digestion 
protocol, two other proteins in the neurotrophin family, NT-3 and GDNF, can also be 
detected at trace level by signature peptide method. The LOD is approximately 5 pM for 
BDNF and NT-3, and 10 pM for GDNF, corresponding to 40 and 80 amol protein digest 
injected to the cLC-MS system. This method is potentially useful for realizing sensitive 
and  multiplexed quantification for neurotrophin.  
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Chapter 5 will discuss about possible future directions and will include some 
preliminary data.  
Appendices will document supplemental figure for chapter 3 and several other 
projects including:  
(1) Signature peptide and micro-channel ELISA methods for measuring trace level 
protein markers in the spent medium of ex vivo–produced oral mucosa equivalent 
(EVPOME).  
(2) Polymer monolithic column fabrication for neuropeptide extraction.  
(3) BDNF ELISA result. 
The merits and limitations of each method will be discussed.  
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Chapter 2  
 
Rapid Preconcentration for LC-MS Assay of Trace Level Neuropeptides 
 
2.1 Introduction 
Neuropeptides act as neurotransmitters, neuromodulators, growth factors and 
hormones in the central nervous system. They are involved in physiological and 
pathological pathways such as learning, appetite control, depression, addiction, and 
reproduction
2,190-193
. Monitoring extracellular concentrations of neuropeptides can 
provide insights into their dynamics and physiological roles within the brain
6,50,194
. Such 
measurements are performed by microdialysis sampling followed by assay for peptides of 
interest in collected fractions. Measurement of neuropeptides is challenging due to their 
low extracellular concentration (usually pM level) and tendency to degrade during 
storage
195
. The difficulty is further exacerbated by low recovery of microdialysis 
sampling
196
; although recent developments have illustrated routes to improved 
recovery
119,120,125
. Measurement is also hampered by slow analysis times. Thus, despite 
their importance, neuropeptides are infrequently measured in vivo relative to other 
neurotransmitters. In this work, we describe an approach to increase the throughput of 
neuropeptide measurements while maintaining sufficient sensitivity.  
Capillary zone electrophoresis
197,198
, high performance liquid chromatography (HPLC) 
137,141,199-202
 and radioimmunoassay
203,204
 have been applied for determining the in vivo 
concentration of neuropeptides. Since seminal work by Caprioli
142
, electrospray 
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ionization (ESI)-multistage mass spectrometry (MS
n
) has gained popularity for such 
measurements due to low amol detection limit from microliters of samples, high 
specificity, and multi-analyte capacity
19,140,142,205
. Although ESI-MS
n
 is a useful method, 
the high salt content and low concentration of neuropeptide mean that they must be 
preconcentrated, desalted, and separated, typically by LC or solid phase extraction, for 
analysis
206
. Use of cLC columns is critical because it allows the microliter samples to be 
concentrated on packed beds with nanoliter volumes to improve sensitivity
142
. This 
method has achieved limits of detection (LOD) as low as 0.5 pM from 4 μL volume 
samples of opioid neuropeptides, making it suitable for in vivo measurements.  
A limitation of cLC-ESI-MS
n
 for high sensitivity neuropeptide measurements is its 
low throughput. When using columns with small bore (25-50 μm) packed with 5 μm 
reversed phase particles, loading a few microliter sample can take as long as 15 min, even 
at high pressures (4000 psi), and yield overall analysis time of 20-30 min/sample
18,19
. 
Narrow bore columns may also be prone to clogging, especially when repeatedly loading 
large volume of samples, which can further reduce throughput due to frequent column 
changes. Low throughput is a significant concern because microdialysis generally 
produces many sample fractions over the course of a single experiment. Neuropeptide 
degradation, which is frequently observed for trace concentrations found in brain 
samples
207
, places a further premium on rapid analysis.  
To accelerate analysis in capillary LC-MS
n
, flow rate during preconcentration and 
column rinsing must be increased since these are rate limiting steps; however, it is 
unclear if more rapid preconcentration can be achieved while maintaining the low LOD 
needed. At a given pressure (e.g., the maximal pressure of the system) flow rate is 
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directly proportional to the square of both column I.D. and particle diameter 
208
. In this 
chapter we improved throughput of neuropeptide analyses by: (1) using larger bore 
capillary columns (75 μm I.D.) packed with larger diameter (10 μm) reversed phase 
particles for lower pressure loading and rinsing; (2) determining the flow rate limits for 
operation; and (3) developing a periodic column washing scheme to maintain column 
stability under repeated injections. As a demonstration of the method, LE and ME) were 
detected in microdialysis samples collected in vivo from rat GP. The enkephalins are 
endogenous opioid ligands with important roles in many processes such as pain inhibition 
209
, addiction
210
, feeding
6
, and movement
51
. Rapid assays for these and related peptides 
will facilitate studies of their role in normal and pathological brain chemistry. 
2.2 Materials and methods 
2.2.1 Chemicals and materials 
Fused silica capillary was from Polymicro Technologies (Phoenix, AZ). Solvents for 
capillary LC were Burdick and Jackson from Honeywell (Muskegon, MI). Alltima C18 
packing materials (10 μm, 5 μm) were from Grace Davison (Deerfield, IL). Formic acid, 
hydrofluoric acid and isopropanol were from Fisher Scientific Inc. (Ann Arbor, MI). 
Enkephalins, high purity acetic acid and formamide were purchased from Sigma-Aldrich 
(Saint Louis, MO). DynA1-8 was from Phoenix Pharmaceutical Inc. (Belmont, CA), 
Kasil
TM
 1624 and K
TM
 sodium silicates were from PQ Corporation (Malvern, PA). 
Artificial cerebrospinal fluid (aCSF) used for making neuropeptide standards and 
microdialysis perfusion was made to a final concentration of  145 mM NaCl, 2.68 mM 
KCl, 1.10 mM MgSO4, 1.22 mM CaCl2, 0.50 mM NaH2PO4, and 1.55 mM Na2HPO4 
with MiliQ
TM
 water (EMD, MiliporeBillerica, MA), and pH was adjusted to 7.4 using 1 
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M NaOH. High potassium aCSF solution has the same composition as regular aCSF 
except a combination of 75 mM KCl and 70 mM NaCl was used to substitute the 145 
mM NaCl in regular aCSF. aCSF was stored at 4 
0
C  and was filtered with 0.2 μm pore 
filters (GE, Piscataway, NJ) to remove particulates prior to experiment. 
2.2.2 Capillary LC 
Capillary columns were prepared in house using 75 μm I.D. /360 μm outer diameter 
(O.D.) fused silica capillary. A 1 mm silica sol-gel frit was placed at one end of the 
column using a slightly modified version of a method previously described
19
. In brief, a 
20 cm long capillary was filled with a mixture of  3:1:1 (v/v/v) Kasil
TM
 1624: K
TM
 
sodium silicate: formamide up to 5 cm by capillary force, and then placed in an oven 
(100 
o
C) overnight for polycondensation of the silica sol-gel network. The capillary was 
cut by a ceramic capillary cutter (Polymicro Technologies) to leave a ~1 mm section of 
the sol-gel network as a single-ended frit. The capillary frit was flushed with water and 
methanol prior to packing. The column was packed with a slurry of 10 μm AlltimaTM C18 
reversed phase particles (5 mg/ml particles in acetone) at 200 psi to 3.6 cm.  The open 
end of the capillary was also cut to leave only 0.4 cm void capillary to minimize dead 
volume, resulting in 4 cm total column length. The electrospray emitter was prepared in 
house using 20 cm of 40 μm I.D./360 μm O.D. fused silica capillary. A 1 cm section of 
polyimide coating 10 cm away from one end was removed with flame to expose bare 
silica that was pulled into two separate tips by a P-2000 CO2 laser puller (Sutter 
Instruments, Novato, CA). The tip was etched with 49% hydrofluoric acid for 3 minutes 
to create the electrospray emitter, and the emitter was cut at the open capillary side to a 
length of 1.3 cm.  The column and emitter tip were joined by a 2 cm long 
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polytetrafluoroethylene (PTFE) tubing (1/16”X0.010”, Grace Davison, Deerfield, IL). 
The LC method is performed semi-automatically using the system depicted in Figure 2.1 
as follows: (A) manually load 5 μL sample loop with sample using syringe and while 
(re)equilibrating column with loading solvent (0.1% formic acid) under 3600 psi; (B) 
switch injection valve and inject peptide standard under 3600 psi plus rinse with 
additional 5 μL loading solvent; (C) switch injection valve out of line and rinse column 
with another 5 μL loading solvent to remove remaining salt from column; and (D) switch 
selection valve to lower pressure pump with mobile phase to elute peptide(s) for 
detection. 
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Figure 2.1 Diagram and operation scheme of the dual valve dual pump LC-MS
n 
system. Valve positions 
shown for filling sample loop (A), sample injection onto column (B), rinsing column (C), and peptide 
elution and detection (D). Pump 1 is a Waters 626 HPLC pump (Waters Corporation, Milford, MA) 
operated with elution mobile phase and pump 2 is a Isco 100D high pressure syringe pump  (Teledyne Isco 
Inc., Lincoln, NE) to drive loading solvent through the column. Detailed description is given in the text. 
2.2.3 MS detection 
The LC system was coupled to a quadrupole ion trap (QIT) mass spectrometer (LCQ 
Deca XP Plus, Thermo Fisher, Waltham, MA) operating at positive mode with a Finnigan 
nanospray ionization source (Thermo Fisher Scientific, Waltham, MA). All 
measurements were made with the following setting: automatic gain control (AGC) on, 
(A) (B) 
(C) (D) 
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collisional induced dissociation (CID) q = 0.25, isolation width m/z = 3, activation time 
0.25 ms, number of micro scan = 2, maximum injection time = 400 ms. Normalized 
collision energies were 38%, 33% for LE (MS
3
), 36%, 33% for ME (MS
3
) and 34% for 
DynA1-8 (MS
2
).  Optimization of optics for best sensitivity was done monthly with 
constant infusion of 2 μM ME into the mass spectrometer with a flow rate of 100 nL/min. 
The MS
n
 pathways were: 556397278+323+380 for LE, 574397278+323+380 
for ME as discussed in our previous work
18,140
, 491435 for DynA1-8. Ions were detected 
under consecutive reaction monitoring mode (CRM) or selected reaction monitoring 
mode (SRM) with the following mass range: 277-279,322-324,379-381 for ME and LE, 
434-436 for DynA1-8.  
2.2.4 In vivo microdialysis 
Adult male Sprague–Dawley rats (Harlan, Indianapolis, IN) weighing between 250 
and 350 g were used.  Rats were housed in a temperature and humidity controlled room 
with 12 h light/dark cycles with food and water available ad libitum. All animals were 
treated as approved by the University of Michigan Unit for Laboratory Animal Medicine 
(ULAM) and in accordance with the National Institute of Health (NIH) Guidelines for the 
Care and Use of Laboratory Animals. Prior to surgery, rats were anesthetized with an 
intraperitoneal (i.p.) injection of a ketamine (65 mg/kg) and dexdormitor (0.25 mg/kg) 
mixture prepared in an isotonic salt solution. Concentric microdialysis probes with 1.5 
mm long PAN active membrane (AN69 from Hospal, Bologna, Italy) with recoveries 
calibrated ex vivo of 9.6% for LE and 8.3% for ME at 0.6 µL/min flow rate were 
implanted under anesthesia into the GP according to the following coordinates from 
bregma and top of the skull: AP -1.3 mm, ML ±3.3 mm, DV -7.0 mm
211
. Probes were 
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secured to the skull by acrylic dental cement and metallic screws. Following surgery, rats 
were allowed to recover and experiments were run 24 h after probe implantation. 
Microdialysis probes were flushed at a flow rate of 1.5 µL/min with aCSF for 2 h using a 
Chemyx Fusion 400 syringe pump (Chemyx, Stafford, TX). Perfusion flow rate was then 
reduced to 0.6 µL/min and samples were collected every 20 minutes into vials containing 
0.5 µL acetic acid to preserve peptide stability as previously described
18
. Samples were 
immediately injected on the LC-MS
n
 system following collection. High K
+ 
aCSF (75 mM) 
was perfused for 40 min through the probe after 3 baseline samples were collected. Lines 
were then switched back to standard aCSF and 3 more samples were collected (Figure 
2.6).  
2.3 Results and discussion 
2.3.1 Influence of column bore size and particle size on sensitivity 
The procedure for analysis by on-column preconcentration LC-MS
n
 is based on 
previous work which has been successful for several neuropeptides
18,140,141
. The dual 
pump system with selection valve allows sample to be loaded onto the column at high 
flow rate but then eluted at a lower flow rate that gives better ESI sensitivity
212,213
 and LC 
performance without requiring an extensive pressure equilibration. Despite these steps, 
the rate limiting step of analysis is preconcentration and rinsing
18,139,140
. In prior work, 
when using a 25 μm I.D. by 4 cm long column packed with 5 μm reversed phase particles, 
15 min was required to inject a 5 μL sample and rinse the column with 10 μL loading 
solvent (i.e. ~1 μL/min). The total analysis time was 30 min when including gradient 
dwell time (i.e. time for the elution gradient to reach the column), gradient elution, and 
column re-equilibration
18
.   
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Injection flow rate could potentially be increased by increasing applied pressure; 
however, without specialized fittings and valves, the system is prone to leakage at 
pressures over 5000 psi. (Pumps with significantly higher pressure are also available but 
much more expensive.) Another solution is to use shorter columns; however, preliminary 
experiments revealed that shorter columns tended lose sample during preconcentration, 
perhaps due to elution during the injection step. To facilitate faster loading, we therefore 
explored larger bore (75 μm I.D.) capillary columns packed with larger diameter (10 μm) 
reversed phase particles to reduce column back pressure. Potential issues associated with 
this method are: (1) worse separation efficiency of larger particles
214
 might result in 
broader elution band that affects detection sensitivity; (2) when the same volumetric flow 
rate is applied for elution, 75 μm I.D. capillary columns have a 9-fold decrease in linear 
flow velocity compared to 25 μm I.D. column. The change in linear velocity also changes 
separation efficiency 
214
, further complicating system performance determination.  
To explore these effects, we made LE calibration curves comparing columns with 
different I.D.s and particle sizes under the same loading and elution flow rate. As shown 
in Figure 2.2 A, increasing column diameter from 50 μm to 75 μm resulted in an 18% 
increase in calibration curve slope while increasing particle size from 5 μm to 10 μm 
resulted in a 6% decrease in calibration curve slope. Since the calibration curve slope 
variation was already 10% between columns with the same I.D. and particle size, these 
data show that column and particle size had minor effects on detection sensitivity. The 
full width at half maximum (FWHM) of the LE peak using 10 μm particles was  7.4% 
±6.2% (n=3) wider than with 5 μm particles (Figure 2.2B). This small change is likely 
due to the strong dependence of peak width on gradient slope for peptides. (Peptides were 
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eluted with a fixed mobile phase of 53% methanol; however, because the column was 
flushed with aqueous solution prior to elution, a “step” gradient was generated in the 
column.) Although 75 μm I.D. columns packed with 10 μm particles gave similar 
performance as the other two tested columns, the flow resistance on this column was 
much smaller, resulting in 15 μL/min injection flow rate at 4000 psi and potential to load 
and desalt 5 μL sample in one minute. However, under the same applied pressure, the 
injection flow rate was 6 μL/min on 50 μm I.D. columns packed with 10 μm particles and 
4 μL/min on 75 μm  I.D. columns packed with 5 μm particle, requiring at least 2.5 min 
and 3.8 min to load and desalt the same 5 μL sample, respectively. Previous studies18,19 
required 10-15 minutes to load and desalt 4-5 L samples using smaller bore (25-50 μm) 
column with 5 μm column packing.  
 
Figure 2.2 Influence of column I.D. and particle size on detection sensitivity. (A) Calibration curve showed 
column I.D. and particle size had little influence on sensitivity under the same volumetric elution flow rate. 
(B) Chromatogram of LE (5 μL 200 pM injected) showed no obvious peak broadening using column 
packed with 10 μm particle compared to column packed with 5 μm particle. All measurements were done 
with 3 replicates. 
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2.3.2 Influence of loading flow rate and elution flow rate on sensitivity 
After establishing that 10 m particles in 75 m I.D. columns could be used with 
little effect on sensitivity but at lower pressures, we investigated the relationship between 
peptide signal and sample injection/rinsing flow rates to determine how rapidly the assay 
could be performed. For these experiments we used a sample volume of 5 μL and 10 μL 
of loading solvent to rinse the column. (The volume of rinsing solution needed was 
determined in separate experiments. If lower volumes were used, less stable signals were 
achieved, presumably due to interference from salts and other sample constituents that 
are not fully washed away.)  The experiments revealed that peptide peak area remained 
stable for loading flow rate from 2.6 to 14 μL/min (Figure 2.3A). Interestingly, above 14 
L/min signal began to decrease for at least one of the peptides. The reason for this effect 
of higher flow rates is not clear. It seems unlikely to be a kinetic limitation to binding 
since the residence time of an unretained species was ~0.5 s under these conditions. 
Calibration curve of all three peptides also showed no sensitivity change when comparing 
injection under low (2.7 μL/min) and high (14 μL/min) flow rates (Figure 2.3B).  
Another way to increase analysis speed is to increase separation flow rate; however, 
increasing volumetric flow rate may also cause dilution of the eluted peptide band and 
worse ESI efficiency
212,213
. We found that peptide signal from a 200 pM standard 
decreased 68%, 57% and 78% for ME, LE and DynA1-8, respectively, when elution flow 
rate increased from 80 nL/min to 225 nL/min (Figure 2.3C). In theory, higher sensitivity 
could be obtained by pushing the electrospray flow rate lower 
212,213
; however, in practice, 
further lowering flow rates will require an extended time period for elution, thus lowering 
throughput.  An elution flow rate of 100 nL/min was selected as a compromise between 
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time and sensitivity. This flow rate allowed baseline separation of 3 peptides in 2 min 
(Figure 2.3D) while maintaining a LOD of 3 pM for enkephalins, and 10 pM for DynA1-8. 
 
 
Figure 2.3 Influence of flow rates on detection sensitivity. (A) Peptide signal remained stable within the 
injection/rinsing flow rate range of 2.6 μL/min to 14 μL/min. (B) Calibration curve under different 
injection/rinsing flow rate (2.69 μL/min v.s. 13.44 μL/min) suggested no major sensitivity decrease when 
injecting peptide under high flow rate. (C). Increasing elution flow rate decreased peptide signal. Peptide 
standard: 200 pM LE, ME and DynA1-8 dissolved in aCSF with 5% HAc.  Injection volume: 5 μL. (D). 
Reconstructed ion chromatogram (RIC) of 5 μL 60 pM neuropeptide being injected onto the column.  All 
measurements were done with 3 replicates. 
The total analysis time under these conditions was 3.8 min/sample (0.4 min for 
sample loading and column re-equilibration, 0.4 min for injection/preconcentration, 0.8 
min for rinsing, and 2.2 min for elution). In previous work using a 25 μm I.D. column 
with 5 μm packing, a total analysis time of 30 min was needed for analyzing one sample 
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with 4-5 μL volume, with approximately the same LOD when using the same quadrupole 
ion trap MS as used in this work. (Better LODs were obtained by using newer MS, eg. 
linear ion trap MS that has higher sensitivity.)
18
 Thus this approach achieves similar 
sensitivity compared to previous results, but in 13% of the time. For an experiment which 
results in collection of 100 samples, analysis could potentially be completed in 6.3 h 
rather than 50 h, saving substantial amount of time.  
Lower detection limit and higher multi-analyte capacity could potentially be achieved 
by using triple quadrupole MS, which has higher duty cycle and higher sensitivity under 
selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) mode. It was 
reported that 16 neurotransimitters were detected in one LC run under MRM mode using 
a triple quadrupole MS. The sensitivity was sufficient to achieve lower pM to nM 
detection limit without preconcentration
215
. However, due to the reported better 
specificity of MS
3  
in detecting enkephalins 
140
 and the fact that triple quadrupole MS is 
not capable of MS
n
 detection , ion trap type MS remains the best option when MS
3
 or 
higher stage MS is  desired for detecting several neuropeptides. 
2.3.3 Improved stability during serial injections 
To test system stability and injection reproducibility, we performed serial injections 
of 30 peptide standards containing 60 pM ME, LE and DynA1-8. The relative standard 
deviation (RSD) was higher than 10% for all three peptides, and the RSD for ME was 
higher than 40% (Table 2.1). We considered several possibilities for this large RSD 
including: (1) loss of particles from the column due to the sudden pressure drop between 
sample injection and elution causing backflow of particles to the inlet side; (2) partial 
clogging causing decreased amount of sample injection and rinsing; (3) build-up of 
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impurities from peptide sample and solvent on the column causing a change in system 
response (e.g. by eluting with peptide or altering preconcentration capacity). By 
inspecting the column and tip assembly under a light microscope, assumptions (1) and (2) 
were eliminated since no clogging or bed length reduction was found.  
Supporting the idea that accumulation of impurities affected the RSD, we found that 
in a similar series of injections in which a “wash” was applied (injection of 20 μL of 
wash solvent containing 60% (v/v) isopropanol, 30% (v/v) ACN and 10% (v/v) water) 
after every 6 assays the peak area RSD was reduced to less than 10% for the enkephalins 
and less than 20% for DynA1-8 (see Figure 2.4A and Table 2.1). Peak area RSD of 
DynA1-8 still remained > 10% could be the result from using SRM while enkephalins are 
detected by CRM. The reason for using SRM to detect DynA1-8 is that it produced an 
easily identifiable daughter ion (c7, m/z = 435), while the MS
3
 spectrum showed no 
major granddaughter ions for quantification. Previous paper
18
 published by us also 
showed mediocre detection limit for DynA1-8 using MS
3
, urging us to use the SRM 
method as alternative for higher sensitivity.  However, since SRM is essentially MS
2
, 
whose specificity is lower than MS
n
 based CRM method, the higher variation in DynA1-8 
peak area is not unexpected.  Although adding the wash step decreased system 
throughput from 3.8 to 4.4 min per sample, it proved to be effective in improving long 
term performance. Improvement of reproducibility could also be obtained through adding 
internal standards. As a demonstration, we monitored the peak area of 60 pM LE and 
deuterated LE we have in lab (dLE, m/z 560) under serial injection. Although using 
deuterated internal standard has potential issue such as chromatographic isotope effect, 
we have carefully examined the retention time of LE and dLE and found the difference 
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was negligible. These experiments showed that the RSD of peak area ratio of LE versus 
dLE was reduced to <5%, while peak area RSD of individual peptide was still around 8-9% 
(Table 2.1). Based on these results, we presume that use of stable isotopes of other 
peptides would also aid detection, but this was not tested for cost savings. 
 
Figure 2.4 Chromatogram of serial injections of 60 pM peptide standards in series. A wash injection with 
20 μL60:30:10 (v/v/v) isopropanol: ACN: H2O injected onto the column was carried out every 6 injections. 
The right image shows a zoomed-in view of one injection where 5 μL peptide standard was preconcentrated, 
rinsed, and separated for detection within 4 minutes. 
Table 2.1 Peak area RSDs of tested neuropeptides under different injection protocols. Adding wash 
injection and injecting peptide with internal standard significantly improves injection reproducibility. 
Injection type Peak Area RSD 
(DynA1-8) 
Peak Area RSD 
(LE) 
Peak Area RSD 
(ME) 
No  column rinsing (n=30) 20.2% 18.5% 46.0% 
Wash injection every 6 
injections (n=27) 
15.4% 8.4% 9.1% 
 Peak Area RSD 
(dLE) 
Peak Area RSD 
(LE) 
Peak Area ratio 
RSD (LE/dLE) 
Injection of LE and internal 
standard (with wash 
injection) (n=27) 
9.2% 9.3% 4.3% 
 
The larger columns with rinsing were also found to be resistant to clogging. Under 
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injections with 60 samples injected onto the column. After 60 injections, reduction in 
both injection and elution flow rate and retention time shift was frequently observed, 
indicating partial clogging. Therefore one column was typically used within one day. 
While potentially cumbersome, the ease of packing one such column (~10 min after frit 
preparation), negligible column-to-column retention time shift and small variation in 
calibration curve shape (~10%) mean that these columns are “disposable”. Previous work 
found that 25 μm columns could only survive 20-40 injections, with column-to-column 
peak area variation up to 50%
18
.  
2.3.4 Detecting enkephalins in microdialysate 
To demonstrate the feasibility of this method for in vivo peptide measurements, we 
used it to monitor enkephalins in microdialysis fractions collected at 20 min intervals 
under basal conditions and while perfusing 75 mM K
+
 aCSF through a probe implanted 
in the GP brain of freely moving rats (n = 3), as summarized in Table 2.2.  Microdialysis 
flow rate was set to be 0.6 μL/min,   and 5 μL of the 12 μL dialysate collected over 20 
min was actually injected onto the column.  Excess dialysate was required to overfill the 
loop. More efficient use of such precious samples may be achieved by partial loop and 
“microliter pickup” mode using commercial autosamplers18. The concentration of 
peptides in dialysate samples was determined by external calibration using standard 
solutions of peptide dissolved in aCSF (5% HAc added) with the following 
concentrations: 5 pM, 50 pM, 800 pM, and 3 nM. Calibrations were linear with 
correlation coefficients of 0.99.  
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Table 2.2 ME and LE’s basal and stimulated concentration in in vivo dialysate. In vivo concentration was 
corrected by the relative recovery of the microdialysis probe. 
Collection condition [ME] ± SEM (pM) 
(n = 3) 
[LE] ± SEM (pM) 
(n = 3) 
Basal, dialysate 14.2 ± 1.3 7.1 ± 0.9 
Stimulated, dialysate 1833 ± 149 412 ± 71 
 
To determine if concentration determined by external calibration was accurate, we 
also performed study on matrix effect.  Spiking 5 pM, 50 pM, 800 pM, 3000 nM LE into 
dialysate gave a similar calibration curve as the same concentration in aCSF (Figure 
2.5A). This suggests that matrix effects were negligible in the calibration of peptide 
concentrations. To better examine this effect at low concentrations, we compared peak 
area of 5 and 50 pM LE standards to that found for spiking the same concentrations into 
dialysate. The difference in peak area between the aCSF and spiked dialysate 
corresponded to 5.0 ± 2.8 (SD) pM (n = 3, from 1 rat) (Figure 2.5B), while LE’s 
concentration in dialysate was determined to be 7.1 ± 0.9 (SEM) pM (n = 9, from 3 rats) 
by external calibration, which was not significantly different. This result further suggests 
minimal matrix effect on signal and that external calibration can be used.   
Stability of the dialysate sample signal was examined under serial injection 
conditions. 9 basal dialysate fractions collected from 1 rat over 3 h were serially injected 
over 37 min (9 samples plus 1 wash injection). These samples showed 21% and 22% 
peak area RSD for LE and ME, respectively (Figure 2.5C). The RSD was higher than 
standards possibly because of natural variation of brain peptide concentration over this 
period. Average concentrations of LE and ME in serial injection were determined to be 
5.8 ± 1.3 (SD) pM and 14.4 ± 3.2 (SD) pM, respectively. The basal dialysate 
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concentration determined from 3 rats were 14.2 ±1.3 (SEM) pM and 7.1± 0.9 (SEM) pM 
for ME and LE, again showed no significant difference.  
 
Figure 2.5 In vivo measurement of LE and ME from rat brain dialysate. (A). Calibration curve of LE and 
ME from 5 pM to 3 nM (n = 3) (B) LE’s peak area in 5 pM/50 pM standard and dialysate spiked with 5 
pM/50 pM LE. (C). Serial injection of 9 basal dialysate sample in 37 minutes. Injection volume: 5 μl. 
The basal extracellular concentration for ME and LE was 171±22 (SEM) pM and 
74±12 (SEM) pM when correcting for in vitro recoveries (8.3% for ME and 9.6% for LE). 
Peviously published results reported that the total enkephalin concentration in rat globus 
pallidus/ventral pallidum was 150 pM, with ME/LE ratio ranging from 1.3:1 to 3.0:1. Our 
data gave a total of 245 pM, indicating reasonable agreement.   
0 10 20 30 
Time (min) 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 
20.0 21.0 22.0 23.0 24.0 
Time (min) 
   0 
Time (min) 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 
Time (min) 
TIC 
LE 
ME 
20.0 1.0 2.0 
(C) 
0 1000 2000 3000
0.0
2.0x10
8
4.0x10
8
6.0x10
8
8.0x10
8
 LE
 ME
 LE, spiked
P
e
a
k
 A
re
a
Concentration (pM)
0.0
2.0x10
6
4.0x10
6
6.0x10
6
8.0x10
6
50 pM 
P
e
a
k
 A
re
a
 LE
 LE, spiked
5 pM
Concentration added to dialysate
(A) (B) 
52 
 
K
+
 stimulation causes depolarization of the neuronal cell membrane and subsequent 
neuropeptide level into the extracellular space 
216,217
. In this study, perfusion of 75 mM 
K
+
 aCSF into the brain caused 129 fold and 58 fold increase in ME and LE’s in vivo 
concentration, respectively (Figure 2.6). Previous microdialysis-RIA based method 
reported that turning on K
+
 stimulation for only 2 min in a 30-min long collection period 
caused collected opioid peptide (majorly enkephalins) increase from 1.5 fmol to 43.9 
fmol in globus pallidus/ventral pallidum
195
. Another study using microdialysis coupled 
online to capillary LC-MS
2
 reported K
+
 stimulation over 30 minutes caused 32 and 19 
fold increase in ME and LE concentration in GP, respectively
141
. The variation in 
enkephalin level increase could be contributed to the fact that previous results were 
obtained from anesthetized rats using 4 mm probe, while our results were from freely 
moving rats with 1.5 mm probe. Freely moving rats tend to have different response under 
potassium stimulation 
140
, and longer probes are less likely to be placed accurately in the 
targeted brain area. In addition, the K
+
 concentration in this study was 75 mM, while 
previous studies used 100-150 mM K
+
 for stimulation.   Nonetheless, the reported results 
along with our observation was in agreement with the fact that the GP is the primary 
target of striatopallidal neurons which express high levels of enkephalins 
218,219
. Thus, 
depolarizing the neurons directly at the terminal site of enkephalin release likely yields 
higher release levels compared to measuring in other areas such as the striatum where the 
cell bodies of striatopallidal neurons reside.   
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Figure 2.6 K
+
 stimulation profile of ME and LE. Potassium concentration: 75 mM. Stimulation time: 40 
minutes. Number of replicates: 3. Error bar represents standard error of mean (SEM). 
Other studies also had suggested milder increases in enkephalin levels upon K
+
 
stimulation in striatum. For example, enkephalins increase in rat striatum was less than 
10 fold under K
+
 stimulation
18,140
.  
2.4 Conclusions 
The method described in this chapter has demonstrated fast neuropeptide analysis 
with low pM detection limits. With ~4 min cycle time per sample, the throughput was 
improved 5-8 fold over previous work. This method was also validated for in vivo 
measurement where lower amol of enkephalins could be detected from rat brain dialysate. 
The enhanced analysis speed and column stability suggest the possibility of routine 
processing of many in vivo samples.  SIL peptides will likely be needed for cases where 
small changes in peptides are to be measured. Further, as characteristic peptides are 
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increasingly used to quantify proteins, the general approach of rapid loading and rinsing 
may be of utility for trace analysis in other applications as well.  
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Chapter 3  
 
Improving Capillary LC-MS Detection and Microdialysis Sampling for in vivo 
Monitoring of Intact Orexins 
3.1 Introduction 
Neuropeptides are an important class of signaling molecules in the brain that are 
implicated in functions as diverse as feeding, stress, pain, and sleep. Neuropeptides, 
which are formed by processing precursor proteins translated from genes, are released 
into the extracellular space by exocytosis from neurons to exert effects on neighboring 
neurons through binding to cell surface receptors. Regulation of neuropeptides can be 
studied by measuring tissue content of peptide or mRNA; however, better understanding 
of their regulation and function can be achieved by monitoring their extracellular 
concentration dynamics in vivo. Such measurements allow for direct correlation between 
extracellular concentration and behavior, drugs, disease state and other signaling or 
modulation processes
6,8,60,80,220
. A potentially useful technique for such measurements is 
microdialysis sampling. In this technique, a semi-permeable membrane probe is inserted 
into a specific brain region. The probe interior is perfused so that molecules released into 
extracellular space can diffuse across the membrane, enter the probe, and be collected for 
analysis.
221,222
 Collecting a series of fractions allows temporal information to be 
obtained.
223,224
 Microdialysis is favored over other sampling methods because it disturbs 
relatively little tissue
225,226
 and produces sample that is free of proteins and tissue debris. 
Although microdialysis is routinely used for small molecule neurotransmitters, its use for 
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monitoring peptides remains relatively rare and challenging due to low extracellular 
concentration of peptides (1-100 pM) and small samples generated (1-10 µL). Analytical 
challenges are exacerbated by low recovery of neuropeptides through microdialysis 
probes. In this chapter we describe procedures to improve sensitivity and recovery of 
neuropeptides.   
Historically neuropeptides have been assayed in dialysate by radioimmunoassay (RIA) 
or enzyme linked immunosorbant assay (ELISA). Although immunoassays with 9-100
40 
attomole mass limit of detection (LOD) have been reported for neuropeptides, it can be 
difficult to develop and maintain assays with this sensitivity. Furthermore, immunoassays 
lack sequence specificity leading to potential false positives in quantification and 
inability to discern modified or degraded peptides
199,227
.  
An emerging method for trace neuropeptide detection is capillary liquid 
chromatography coupled to mass spectrometry (cLC-MS)
17-19,142,205,228,229
. With this 
method, microliter samples of low abundance peptides can be concentrated onto a 
nanoliter volume column to enable detection of specific peptides at low picomolar 
concentration (attomole quantity)
18,19,38,140
. Despite its potential for high sensitivity and 
specificity, only 10 of the over 200 known mammalian neuropeptides have been 
quantitatively measured at their endogenous concentration in vivo using this 
technique
18,19,38,39,139-142,205,228
. Successes have been mostly limited to small peptides 
(molecular weight, MW < 2000 Da). (An exception was β-endorphin, which was 
enzymatically digested to form a signature peptide fragment that was easier to detect with 
cLC-MS
18
.) One reason for difficulty in applying cLC-MS to determination of 
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neuropeptides is widely disparate detection limits. A previous study showed that a 
selection of 10 neuropeptides had LODs from 0.5 pM to 10 nM from 4 µL sample
18
.  
Work on peptide drugs and tryptic peptides for shotgun proteomics applications has 
shown that adsorption to surfaces, such as sample vials, causes peptide loss and poor 
injection repeatability
102,230
. Addition of organic solvent, including ACN
143,231
, ethanol
102
, 
and dimethylsulfonate (DMSO)
232
 to sample was shown to be effective in preventing 
non-specific adsorption loss and improved LOD to mid-to-high amol range
29
 for peptides 
with MW < 2000 Da. This concept was extended to 3 neuropeptides in standard samples 
and dialysate
143
. Although promising, it remains questionable how widely applicable this 
approach is and whether organic additive to dialysate samples can provide enough 
improvement for in vivo detection of larger neuropeptides such as β-endorphin and 
orexins, where poor LC-MS sensitivity may have more complicated origin, such as 
multiple charge state in ESI-MS.   
Another challenge for in vivo neuropeptide monitoring is low recovery of peptides by 
microdialysis probes. Previous studies have reported relative recovery from 0.28%-1.5% 
for β-endorphin (3467 Da), orexin A (3561 Da) and Gal (3157 Da)5,63,75. Ways to 
improve recovery include using high molecular weight cut-off (MWCO) membranes, 
blocking protein in perfusion media, push-pull microdialysis, and affinity-enhanced 
microdialysis
36,120,124,233
. While potentially effective, these methods do not prevent 
adsorption to the membrane itself and in some cases may complicate cLC-MS analysis. 
Microdialysis catheter modification has been investigated for reducing adsorption loss; 
however, published methods focus on reducing adsorption loss to hydrophobic membrane 
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and tubing surface
5,101,103
. Preventing sample loss when using an already hydrophilic 
membrane (such as AN69 membrane) and tubing has not been reported.  
In this chapter, we evaluate and combine two methods to improve neuropeptide 
detection by reducing their loss during transport from brain to mass spectrometer. Adding 
ACN to dialysate sample was found to make LODs more similar and improved all LODs 
to 0.1-2 pM for 8 µL samples for a selection of 10 neuropeptides. The ACN percentage 
for each individual peptide was found to have an optimal value that correlated with 
peptide MW and retention time on a reverse phase LC column. We also improved probe 
recovery for several peptides by treating the dialysis membrane and fused silica tubing 
with polyethyleneimine (PEI). The effect appeared to be due to reducing electrostatic 
interaction between peptides and the microdialysis probe since modification increased 
recovery for peptides that carried net positive charge.  
As a demonstration of utility of these approaches, we show that the method allows 
recovery and detection of intact orexin A and orexin B (2936 Da) from rat arcuate 
nucleus in vivo. Orexins are neuropeptides that regulate sleep-wake cycle and feeding 
behavior
4,234
. Monitoring their concentration in vivo may provide useful information on 
their in vivo processing and function. From the same samples we also detected a fragment 
of rat POMC that has a sequence identical to mouse β-endorphin. This result 
demonstrates the power of using sequence specific detection.   
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3.2 Materials and methods 
3.2.1 Chemicals and materials 
Orexin A, B, β-endorphin (mouse, rat), CCK-4, Gal, and OFQ were from Phoenix 
pharmaceuticals (Burlingame, CA). α-MSH, deacetylated -MSH and DynA1-17 were 
from American Peptide Company (Sunnyvale, CA). HPLC grade solvent, including water, 
methanol (MeOH) and ACN were purchased from Honeywell (Muskegon, MI). LC-MS 
grade formic acid (FA) and glass auto sampler vials, inserts were from Fisher Scientific 
(Waltham, MA). PEI (average Mn = 1800 by gel permeation chromatography, average 
MW = 2000 by light scattering, 50 wt% in H2O) and Sub P were from Sigma-Aldrich (St. 
Louis, MO). Ringer’a solution consisting of 148 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2 
and 0.85 mM MgCl2 was used as microdialysis perfusion media for both in vivo and in 
vitro experiments. High K
+ 
Ringer’s solution was the same except that KCl’s 
concentration was raised to 100 mM with NaCl concentration reduced to keep the same 
ionic strength. Fused silica capillaries were purchased from Molex (Phoenix, AZ) and 5 
µm Alltima
TM
 C18 packing was from Grace Davison (Waltham, MA).  
3.2.2 Microdialysis probe modification and in vitro recovery determination 
Microdialysis probes for both in vitro and in vivo studies were constructed in-house in 
concentric style using AN69 polyacrylonitrile membrane (Hospal, Bologna, Italy) with 
300 µm outer diameter (O.D.), 2 mm active membrane length. The probe inlet was 
connected to a section of 127 µm inner diameter (I.D.) FEP tubing with 10 µL dead 
volume (Zeus, Orangeburg, SC), and the outlet to a 100 µm I.D./360 µm O.D. fused 
silica capillary. PEI modification of the probe was achieved by immersing the probe into 
a stirring vial containing 5% PEI and pumping 5% PEI solution through the probe and 
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tubing at 0.5 µL/min for 12 h. After modification, the catheter was washed by Ringer’s 
solution at 1 µL/min for 8 h to remove unabsorbed PEI.  To measure in vitro recovery, 
the probe was placed in a stirring vial containing 1 nM peptide in Ringer’s solution. 
Fractions were collected for 20 min while perfusing the probe at 0.5 µL/min. The 
collection vial was pre-loaded with the proper volume of ACN and FA to result in 
optimal ACN percentage and 0.5% FA in the fraction.   
3.2.3 In vivo microdialysis sampling from freely moving rats 
Adult Sprague-Dawley rats (Harlan Laboratories, Inc.) were used for all experiments.  
Rats were housed in a temperature and humidity controlled room with 12 h light/dark 
cycles with access to food and water ad libitum. Animals were treated as approved by the 
University of Michigan Unit for Laboratory Animal Medicine (ULAM) and in 
accordance with the National Institute of Health (NIH) Guidelines for the Care and Use 
of Laboratory Animals.  In addition, all animal experiments were conducted within the 
guidelines of Animal Research Reporting in vivo Experiments (ARRIVE). Prior to 
microdialysis probe insertion, rats were anesthetized using an isoflurane vaporizer and 
placed in a Model 963 stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA).  
Probes were inserted into the arcuate nucleus immediately after completion of removing 
excess PEI, using the following coordinates from bregma and top of skull (Franklin and 
Paxinos 2008): AP -2.2 mm, ML ±1.0 mm, DV -10.0 mm implanted at 3.5° angle.  The 
probes were secured with skull screws and acrylic dental cement.  Following surgery, rats 
were allowed to recover for 24 h with free access to food and water.  Microdialysis 
probes were flushed at a flow rate of 2 μL/min with Ringer’s solution for 1 h using a 
Fusion 400 syringe pump (Chemyx, Stafford, TX, USA). Perfusion flow rate was then 
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reduced to 0.5 μL/min and allowed to flush for an additional 1.5 h prior to baseline 
collections. Microdialysis fractions were collected at 20 min intervals. For each 
experiment, 4 fractions were collected at baselines, 3 during high-K
+
 perfusion, and 2 
post-stimulation. When experiments were completed, animals were sacrificed and the 
brains were extracted for histology. 
3.2.4 Capillary LC-MS  
Column and emitter tip preparation are described in detail elsewhere
38
.  Briefly, a 8 
cm length of 75 /360 µm I.D./O.D. fused silica capillary (frit length of ~0.5 mm in the 
exit end) was slurry-packed with a 5 mg/mL 5µm Alltima
TM
 C18 slurry to a length of 4 
cm. The frit end was connected to a fused silica electrospray emitter tip through a Teflon 
tubing connector. The tip-column assembly was connected to a dual-valve, dual-pump 
LC system as depicted in Figure 3.1.  The system consisted of two 6-port Cheminert  
valves (Valco, Houston, TX ), a high pressure syringe pump (Teledyne Isco, Lincoln, NE) 
and an Agilent 1100 HPLC pump (Santa Clara, CA). All tubing connections, including 
sample loop and sample needle, were made from 360 µm O.D. fused silica capillaries. 
Operation of the system has been described elsewhere
18
. Mobile phase A (MPA) was 0.1% 
FA in water and mobile phase B (MPB) was 0.1% FA in MeOH. The high pressure pump 
operated at 3500 psi to deliver loading solvent (0.1% FA) at 5 µL/min onto the column.  
The auto sampler was equipped with a 16 µL sample loop and operated at partial loop 
mode. 8 µL sample was loaded into the sample loop and injected, retained and rinsed on 
the column head using 3 min injection time and 2 min rinsing time. The LC plumbing in 
contact with peptide solution was highlighted in Figure 3.1. After injection the sample 
needle was washed by 100 µL wash solvent containing 50% MeOH, 50% water and 0.2% 
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FA to prevent carry-over. The HPLC pump was then switched to the column to elute 
peptides with the following gradient: 0.0-1.5 min: 5%-95% MPB，1.5-7.0 min: 95% 
MPB, 7.0-7.1 min: 95%-5% MPB, 7.1-10.0min: 5% MPB. Elution flow rate was 150 
nL/min.  
The capillary system was coupled to a linear ion trap (LTQ XL, Thermo Scientific) 
mass spectrometer operating at positive ion mode. Peptides were detected either in MS
2
 
or MS
3
 mode by collision induced dissociation depending on the sensitivity of each mode 
on individual peptide. Detection was achieved with the following parameters: spray 
voltage = 2.0 kV, capillary temperature = 150 
o
C, automatic gain control (AGC) on, q = 
0.25, isolation width = 3 m/z, activation time = 0.25 ms, number of micro scan = 1. 
Fragmentation pathways of each peptide were listed in Table 3.1.  To maintain ion optics 
for best peptide sensitivity, the linear ion trap was tuned bi-monthly by infusing 2 µM 
orexin A solution dissolved in 50:50 MeOH: water, 0.2% FA, and monitoring daughter 
ion at m/z = 854.  
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Figure 3.1 Dual pump dual valve system connection. Tubings in contact with peptides are highlighted in 
red. Sample needle, sample loop and connection tubing between the injection valve and column were all 
made from fused silica capillaries.  
3.3 Results and discussion 
3.3.1 Addition of organic additive to reduce post collection, pre-column peptide loss 
Previous work showed that using 25 µm bore columns, 90 nL/min elution flow rates, 
and extensive on-column concentration with large volume injections (4-5 µL loaded onto 
8 nL volume columns), it was possible to obtain detection limits as low as  0.5 pM-1 pM 
for enkephalins. However, detection limits were uneven, with other peptides having 
higher LODs such as Sub P (10 nM) and intact β-endorphin (5 nM). Subsequent study 
revealed that many of the peptides with poor LODs also generated significant carry-over, 
i.e. signals for peptide during injections of blank solutions after a sample injection 
(Appendix D). These observations suggested that adsorption to surfaces as peptides were 
transported from vial to column were causing both effects. Organic modifier added to 
samples had previously been shown to improve sensitivity for tryptic peptides
231,232
 and 3 
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neuropeptides
143
. Therefore we investigated the effect of acetonitrile added at different 
concentrations (5-30%) to a panel of 10 neuropeptides with MW ranging from 597 to 
3561 (see Table 3.1) dissolved in ringer solution.  
Table 3.1 MS
2 
or MS
3
 pathways for selected neuropeptides. Daughter ions and granddaughter ions were 
selected based on intensity with direct infusion of 2 µM peptide standard. Three most intense transitions 
were selected for quantification unless the peptide only produced one or two predominant fragments, in 
which case only 1-2 daughter ions were selected.   
Peptide M.W. MS pathway 
CCK-4 596.7 597.7580 (b4)552(b4-CO),449(WMF-NH3),334(WM) 
OFQ 1809 453.4 ([M+4H]
4+
)536(y153+),555(b163+) 
α-MSH 1665 556([M+3H]3+)513(y82+), 687(y112+), 544([b13-NH3]
3+
) 
Deacetylated α-
MSH 
1623 406.8([M+4H]
4+
)458.5(y113+) 
DynA1-17 2147.5 538([M+4H]
4+
)529.3,(b133+)  630.0(b153+), 668.1(b163+) 
Sub P 1347.6 450.0([M+3H]
3+
)600.3(b102+)254.0 (RP), 591.5 ([b10-
H2O]
2+
), 946.5(KPQQFFGL-H2O) 
Gal 3164.5 528.5([M+6H]
6+
)554.7(y204+), 581.7(a275+), 609.7 (y224+) 
Mouse  
β-endorphin 
3436 688.7([M+5H]
5+
)754.4(y274+), 805.5(y294+) ,819.9 (y304+) 
Orexin A 3561 713.3([M+5H]
5+
)854([y32- H2O]
4+
),858.5([b32- H2O]
 4+
) 
Orexin B 2936 735([M+4H]
4+
)693.5([b27-H2O]
 4+
) 
 
As shown in Figure 3.2 A and B, adding ACN to samples increased signal for all 
peptides tested; but, adding too much decreased signal so that each peptide had an 
optimal ACN percentage. We found a positive correlation of the optimal ACN 
concentration to both MW and retention time (Figure 3.2C and D). None of the peptides 
has optimal ACN percentage exceeding 25%.  The maximal optimal percentage was also 
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observed in another study using DMSO as organic additive
232
, where the observed 
threshold was 50% for 10 cytochrome c tryptic peptides in that study. These results can 
be understood by considering that increasing organic modifier decreases the tendency of 
a peptide to interact with solid surfaces by hydrophobic interactions during the injection 
process; however, adding organic modifier also increases the elution strength of the 
sample on the reversed phase LC columns. This in turn reduces the ability of the column 
to capture and stack peptide during large volume injections. Therefore peptides have an 
optimal concentration that increases with potential for hydrophobic interactions, as 
measured by retention. Because increasing molar volume increases dispersion 
interactions, this effect also correlates with MW.    
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Figure 3.2 Adding ACN reduced peptide nonspecific adsorption loss prior to injection. (A), (B): Peptide 
signal (represented by normalized peak area averaged from triplicate injection) affected by ACN 
volumetric percentage at 5% interval, optimal ACN percentage for each peptide is labeled in the graph. (C): 
Impact of peptide molecular weight on the optimal ACN percentage of peptides. (D): Impact of peptide 
hydrophobicity (represented by retention time on a reverse phase column) on the optimal ACN percentage 
of peptides. To correlate retention time with optimal ACN percentage, ACN with 0.1% FA was used as 
MPB and a shallower gradient than the detection gradient was used to better separate peptides: 0-1 min: 
2%-20% MPB, 1-9 min: 20-30% MPB, 9-10min: 30-90% MPB, 10-12min: 90% MPB, 12-12.1min: 90-0% 
MPB, 12.1-15min: 0% MPB. Graph was obtained from 9 replicated injection on three columns.  
 Improvement in peptide quantification was also evaluated by comparing the 
sensitivity and LOD for peptide standard dissolved in totally aqueous solvent and its 
optimal ACN concentration. Table 3.2 shows that adding organic solvent to the sample 
increased peptide detection sensitivity (as indicated by calibration curve slope) up to 23 
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fold, and decreased LOD by 1.4 to 60 fold. The biggest improvement came from the 
biggest peptides such as orexins and mouse β-endorphin, which are more likely to be lost 
due to adsorption as indicated by their optimal ACN percentage. This effect also tended 
to normalize the LODs giving a narrower range (0.1-2 pM) than when injecting from 
ringer solution with 0.5% FA (0.2-30 pM).  Figure 3.3 shows that when injecting orexins 
and mouse β-endorphin with 25% ACN, the linearity of calibration curve (represented by 
R
2
) increased from ~0.8 to above 0.98. Peptide signal reproducibility was also improved 
as indicated by the relative standard deviation (RSD) of the highest concentration injected: 
without ACN, the peak area RSD was as large as 70% at 200 pM for these three peptides, 
while injecting peptides with 25% ACN lowered the RSD down to 3% and 7% at 20 pM 
for β-endorphin and orexin A, and 16% at 10 pM for orexin B, respectively. Injection 
carry-over was also reduced from 20-50% to 1-2% when adding ACN to 25% for orexins. 
It should be noted that without ACN addition, orexin signal could still be observed after 
3-4 blank injections (Appendix D), indicating that in addition to sample vial, the LC 
tubings also serve as active sites for adsorption and subsequent peptide loss.    
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Figure 3.3 Representative calibration curve of the biggest peptides tested, injected with no or 25 % ACN 
added. 25% ACN calibration curve was obtained by triplicate injection of 0, 0.5, 1, 2, 5, 10, 20 pM  (for 
orexin A and mouse β-endorphin) or 0,0.5, ,2,5,10 pM (for orexin B)  peptide standard in ringer solution 
containing 25% v/v ACN, and 0% ACN calibration curve was done by triplicate injection of  0, 5, 10, 20, 
50, 100, 200 pM peptide standard in ringer solution (0.5% FA). 
 
Table 3.2 LOD and calibration curve slope for injections with totally aqueous standard or standard spiked 
with ACN to individual peptide’s optimal value. LOD was calculated by using equations: LoB = 
meanblank + 1.645(SDblank), LOD = LoB + 1.645(SD low concentration sample), LoB=limit of blank, SD=standard 
deviation.  To confirm peptide detection at LOD, peptide calibration curve was made by triplicate 
injections of standards whose lowest concentration was close to the calculated LOD.   
Peptide Optimal 
ACN% 
LOD with 
0% ACN 
LOD with 
optimal 
ACN% 
Slope (pM
-1
) 
with 0% 
ACN 
Slope (pM
-1
)  
with optimal 
ACN% 
orexin A 25 30 pM 0.5 pM 98 1858 
orexin B 25 5 pM 0.6 pM 128 2991 
Mouse β-
endorphin 
25 4 pM 0.6 pM 353 4233 
Gal 20 5 pM 1 pM 251 882 
DynA1-17 15 20 pM 2 pM 54 557 
α-MSH 15 2 pM 0.8 pM 518 1188 
SubP 10 0.5 pM 0.1pM 242 802 
Deacetylated 
α-MSH 
10 0.2 pM 0.1 pM 462 2426 
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CCK-4 10 1 pM 0.7 pM 56 153 
OFQ 10 1 pM 0.3 pM 729 3847 
 
3.3.2 Modifying microdialysis probe to increase peptide in vitro recovery 
Initial in vitro relative recovery measurements were conducted either using in-house 
constructed mirodialysis probes with 2 mm length of AN69 membrane (MWCO = 80 
kDa) or CMA 12 probe with 4 mm long PAES membrane (MWCO = 20 kDa). Orexins 
and β-endorphin recovery was lower than 1% for both probes (Table 3.3 and Figure 3.4). 
AN69 is a hydrophilic membrane with large MWCO
235
, therefore poor peptide recovery 
was unlikely due to adsorption to the membrane through hydrophobic interaction or 
inadequate pore size. AN69 membrane carries negative charge owing to the embedded 
sulfonate group, while most selected peptides in this study have positive charge at pH 7.4 
(Table 3.3) suggesting the possibility that electrostatic interaction affected recovery.  
AN69 has a positively charged version which employs physical adsorption of 
polycationic PEI onto the membrane
95,98
, however, this version, called AN69ST, is 
mainly used in hemodialysis to reduce coagulation and has no demonstrated application 
in neuropeptide microdialysis. In addition, only switching the charge characteristic of the 
membrane does not result in elimination of negative potential in the other parts of the 
microdialysis catheter, such as silanol group on the inner wall of the fused silica capillary, 
which PEI is known to adsorb to
231,232
.   These negatively charged sites might still cause 
electrostatic interaction and loss of peptides. 
To modify the probe membrane and tubing at the same time, we pumped 5% PEI 
through the microdialysis catheter with probe attached prior to use. As shown in Figure 
3.4, PEI-treatment improved recovery for 10 out of 11 neuropeptides tested and the 
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recovery increase was statistically significant for 7 peptides: rat β-endporpin, mouse β-
endorphin, orexin B , Gal, Sub P, deacetylated α-MSH and OFQ (paired t test, p < 0.05). 
CCK-4 was the only peptide which showed slight decrease in recovery after treatment, 
and it carries zero net charge at pH 7.4, while all other peptides carry positive charge. 
Table 3.3 shows the value of relative recovery and recovery improvement after PEI 
treatment, it displays a general trend that smaller peptides with lower charge tend to have 
less improvement in recovery, while bigger peptides with larger net positive charge 
benefit more from the PEI treatment (Appendix D).  
 
Figure 3.4 In vitro recovery comparison of in-house constructed AN69 probe treated or untreated by PEI 
solution. N = 4 for each type of probe. PEI modification significantly increased recovery for orexin B, 
mouse β-endorphin, rat β-endorphin, Gal, Sub P, Deacetylated α-MSH and OFQ (*p<0.05) . In vitro 
relative recovery values for orexins, mouse β-endorphin, α-MSHs and DynA1-17 using 4mm CMA 12 probe 
(n=3) were also plotted. Error bar represents standard error of mean (SEM). 
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Table 3.3 In vitro recovery value for each peptide, peptide size and calculated net charge at pH 7.4.  Net 
charge was estimated using  equation      
      
            
    
    
            
, where N represents 
number of residue/termini and  i and j represent basic or acidic residue/termini, respectively. 
Peptide Recovery –
untreated 
probe (n = 4) 
(%) 
Recovery—
PEI  treated 
probe (n = 4) 
(%) 
Improvement 
in relative 
recovery (%) 
Peptide 
MW 
Net charge 
at pH 7.4 
DynA1-17 0.1 ± 0.04% 8 ± 4% 8300% 2148 +4.0 
OFQ 0.3 ± 0.2% 16 ± 2% 5000% 1809 +4.0 
Deacetylated 
α-MSH 
0.7 ± 0.04% 18 ± 4% 3600% 1623 +2.1 
β-endporpin 
(mouse) 
0.3 ± 0.3% 11 ± 4% 3400% 3436 +4.0 
orexin B 0.5 ± 0.3% 10 ± 3% 2700% 2936 +4.0 
β-endporpin 
(rat) 
0.8 ± 0.4% 12 ± 4% 1400% 3466 +4.0 
Galanin 0.7 ± 0.4% 8 ± 2% 1200% 3165 +1.2 
Sub P 12 ± 5% 33 ± 6% 180% 1348 +3.0 
orexin A 0.08 ± 0.05% 0.2 ± 0.03% 130% 3561 +1 
α-MSH 23 ± 3% 27 ± 4% 17% 1665 +1.1 
CCK-4 49 ± 8% 46 ± 4% -7% 597 0 
 
3.3.3 Detecting neuropeptide using unmodified and PEI-modified AN69 membrane 
probe 
To validate this method for in vivo study, neuropeptide orexins and β-endorphin were 
selected to be monitored from rat arcuate nucleus. Orexins regulate wakefulness and 
feeding behavior
4
. Orexin B has not been measured under in vivo setting, while orexin A 
has been measured in a few cases
5,82
; however, quantification has only been achieved 
with immunoassays which lack sequence specificity. Therefore it remains unclear 
whether intact orexin sequence can be detected in vivo. β-endorphin was previously 
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reported detection from this brain region
61
. Orexin A, orexin B, and β-endorphin can be 
readily assayed simultaneously by the LC-MS assay since they have the same optimal 
ACN%.   
A pilot study that compared analysis of dialysate from unmodified AN69 probe (n = 2) 
and PEI-modified AN69 probes revealed interesting discoveries: 1) PEI-modified probe 
yielded baseline signal for orexin B, while its signal from unmodified probe was much 
lower. Orexin A’s signal intensity was more comparable between unmodified probe and 
modified probe. This finding was in agreement with our previous in vitro recovery 
comparison that PEI treatment significantly enhanced recovery for orexin B, but not for 
orexin A; 2) PEI-modified probe also allowed recovery and detection of a peptide that 
has identical MS
2
 transition to mouse β-endorphin from rat brain; but, this peptide was 
not detected from rats implanted with unmodified probe (Figure 3.5A). This also agrees 
with in vitro probe recovery data that PEI modification resulted in 32 times higher 
recovery for β-endorphin than unmodified probe. Therefore, PEI-modified probes were 
used for further in vivo study of peptides since it recovered higher in vivo signal. Rat β-
endorphin, however, was not detected in the initial pilot study using either probe. Since 
mouse and rat β-endorphin possess different amino acid sequence (Ala26Val26), we 
investigated the potential origin of the mouse β-endorphin sequence in rat brain by 
searching its sequence against rodent data base in Uniprot, and found this sequence in an 
unreviewed rat POMC (entry: Q8K422), which had experimental evidence of existence at 
transcript level. The discovery of mouse β-endorphin sequence in rat brain showed 
capillary LC-MS
2’s high sequence specificity, without MS2, this difference might not be 
able to be distinguished using immunoassay based methods.  
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The validity of external calibration was also examined for its capability of correctly 
monitoring in vivo concentration change. Comparison between dialysate spiked with 0-10 
pM peptides to that of a standard calibration curve revealed no significant difference for 
mouse β-endorphin and orexin B, suggesting that matrix effect was negligible and 
external calibration could be used for quantifying these two peptides. For orexin A, 
however, the standard addition curve had flatter slope compared to standard curve, 
indicating matrix effect suppressed orexin A’s signal at higher concentration, and the 
quantification can potentially be improved by including isotopically labeled orexin A as 
internal standard (Figure 3.5 B).  
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Figure 3.5 Detecting orexins and mouse β-endorphin from rat arcuate nucleus. (A) Overlaid, reconstructed 
ion chromatogram (RIC) for orexin A, β-endorphin and orexin B from in vivo dialysate collected using 
either PEI modified AN69 membrane or unmodified AN69 membrane. (B) Comparison between standard 
addition curve and standard calibration curve. 60 µL dialysate was collected and spiked with proper volume 
of ACN and FA to produce 25% ACN and 0.5% FA in final sample, aliquoted to 6 vials and spiked with 
peptide standard to a final concentration of 0, 0.5, 1, 2 ,5,10 pM. The peptide signal from spiked dialysate 
was normalized to the peptide signal from highest standard (10 pM), and this experiment was repeated in 
triplicates using of 3 rats.  
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3.3.4 In vivo neuropeptide monitoring in rat arcuate nucleus 
To test the approach for monitoring the neuropeptides in vivo, we monitored orexins 
and β-endorphin during a treatment with high K+, a method that can stimulate neuronal 
depolarization and exocytosis (Figure 3.6 A). Baseline concentration of orexins and 
mouse β-endorphin were detectable, however, rat β-endorphin was not detected from any 
of the 6 rats, in either baseline or K
+
 stimulated fractions, despite good in vitro recovery 
of the probe (12 ± 4%) and low LOD (0.8 pM). The fact that rat β-endorphin was 
previously detected using ELISA from this brain region
61
 but not detected in this study 
can be possibly explained by capillary LC-MS’s higher sequence specificity towards 
intact rat β-endorphin, which suggests that the previously detected β-endorphin could be 
another molecule that had similar immunoreactivity. Neuropeptides’ concentration in 
dialysate and extracellular basal concentration are listed in Table 3.4. Orexin A’s 
extracellular concentration was estimated to be 1500 ± 350 pM in this brain region, while 
orexin B’s concentration was only 23 ± 6 pM. The difference here may be contributed by 
the peptides’ different stability against metabolism7,84.  
Table 3.4 Basal concentration of peptide orexins and mouse β-endorphin (n = 6). Basal dialysate 
concentration was calculated by external calibration and corrected for dilution of dialysate by adding ACN 
and formic acid. Basal extracellular concentration was estimated according to average in vitro recovery. 
Peptide Basal ± SEM dialysate 
concentration (pM) 
Basal ± SEM extracellular 
concentration (pM) 
Orexin A 3.0 ± 0.7 1500 ± 350 
Orexin B 2.3 ± 0.6 23 ± 6 
Mouse β-
endorphin 
2.5 ± 0.3 23 ± 3 
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100 mM K
+
 stimulation caused increase in orexin A and B release, but not in mouse 
β-endorphin (Figure 3.6 A), which might indicate the non-synaptic release nature of this 
peptide fragment. For orexins, the increase was only statistically significant (p < 0.05) in 
the third K
+
 stimulation fraction. The orexin level was also kept elevated 1-2 fractions 
post K
+
 stimulation. To investigate the origin of slow response to K
+
 stimulation, in vitro 
probe response to step concentration change was measured. Figure 3.6 B showed that it 
took 3 fractions for neuropeptide level to stabilize upon a step change of sampling 
solution concentration from 1 nM to 6 nM, this observation was in accordance with the in 
vivo data that the third K
+
 fraction had highest peptide level. After sampling solution’s 
peptide concentration dropped from 6 nM to 0 nM, peptide concentration in the dialysate 
fraction showed slow decrease, and did not reach balance after 80 min.  Therefore the 
delay in peptide concentration increase under K
+
 stimulation was likely caused by the 
slow response of the probe. Since the microdialysis probe and outlet tubing had a dead 
volume of ~7 µL, the response time of the microdialysis system can potentially be 
improved by using lower-dead-volume probe and outlet tubing to allow more column 
volume to be flushed using fewer fractions. 
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Figure 3.6 In vivo K
+
 stimulation profile and in vitro probe response to co (A) K
+
 stimulation profile for 
orexin A, β-endorphin and orexin B from in vivo dialysate collected using PEI modified probe. N=6, error 
bar represents SEM. *t test, p<0.05. (B) In vitro probe response to concentration change. Probe was 
sequentially placed in stirring vial containing 1 nM, 6 nM and 0 nM peptide standards. Fraction collection 
started immediately after the catheter’s dead time. Four fractions were collected from each concentration. N 
= 4 probes, error bar represents SEM. 
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3.3.5 Dialysate stability during storage 
One challenge faced by neuropeptide in vivo monitoring is peptide stability after 
sample collection. Previous study showed decreased neuropeptide signal after storage in -
80 
o
C for 24 h, and acidifying dialysate was reported to extend the storage period for 
enkephalins and neurotensin to 4 days
18
. In our study, we found that storing dialysate at 
its optimal ACN percent with 0.5% FA also helped to stabilize orexins and mouse β-
endorphin signal up to day 3 post sample collection (Figure 3.7). The elongated storage 
time offers better flexibility of the analytical method when many dialysate fractions are 
generated within one experiment.  
 
Figure 3.7 Neuropeptide stability after -80 
o
C storage for 3 days. Dialysate was collected from two rats and 
pooled, spiked with 1 nM peptide standard to a final concentration of 10 pM, and aliquoted to auto sampler 
vials. 4 vials were chosen in random for analysis on day 0 to day 3 to examine neuropeptides’ stability over 
storage.  
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3.4 Conclusion 
     In this study we have successfully demonstrated in vivo detection of large 
neuropeptides including orexin A, orexin B and a rat POMC fragment which has identical 
sequence as mouse β-endorphin. This was achieved by enhancing cLC-MS’s sensitivity 
using organic modifier to reduce peptide adsorption loss, and by modifying the probe to 
reduce electrostatic interaction and increase microdialysis recovery. With these 
improvements we were able to detect intact orexins and mouse β-endorphin from in vivo 
dialysate at low pM level. We also demonstrated potential applicability of this method to 
7 other peptides which also benefit from the organic modifier strategy. Further 
improvement in quantification and sampling response is possible by including 
isotopically labeled peptide internal standard and using probe/tubing that has lower dead 
volume.  
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Chapter 4  
 
 Development of a signature peptide method for BDNF detection with picomolar 
detection limit 
 
4.1 Introduction 
Signature peptide method is an emerging substitute for enzyme linked 
immunosorbent assay (ELISA) in protein quantification. This method detects protein by 
measuring one or several of its peptide fragments produced from enzymatic digestion 
(usually trypsin) of the protein using liquid chromatography-mass spectrometry (LC-
MS)
236
. Comparing to immunoassays which detects a single analyte, the signature peptide 
method can simultaneously quantify multiple proteins from one sample
237
. In addition, 
signature peptide method can potentially achieve ultrahigh sensitivity with LOD down to 
amol range when using cLC-MS
18
. Absolute quantification (AQUA) is possible by using 
isotopically-labeled internal standard
167
.   
Although quantification of low abundance protein at low amol range is possible, the 
development of such signature peptide method is usually challenging. The presence of 
protein matrix in the sample can interfere with signature peptide detection and 
quantification by generating highly abundant peptide fragments from other proteins
148
. 
Sample preparation such as immunodepletion
183
, organic solvent precipitation
170
 and 
immunocapture
184
 can simplify mixtures to facilitate target protein detection. After 
extensive fractionation, low-to-mid amol LOD could be achieved
185,188
. Another issue is 
81 
 
that at trace concentrations, low protein digestion efficiency and incomplete digestion can 
result in low signature peptide production and reduced sensitivity. This issue is more 
profound for low abundance protein digestion because of  Michaelis-Menten kinetics
238
 
of proteases such as trypsin, meaning low substrate (protein) concentration leads to lower 
digestion rate and even termination of digestion before completion due to protease self-
digestion. Increasing protease concentration has been applied for improving digestion 
efficiency at low protein concentration, for example, an unconventionally high enzyme-
to-protein ratio (4000:1) was needed to digest N-terminal prohormone of brain natriuretic 
peptide at its limit of quantification (17 pM)
186
. Incomplete digestion can also arise from 
protein structures that affect the accessibility of tryptic sites. In such case, optimal 
denaturation protocol of the analyte protein must be developed
177
.  In addition, different 
digestion protocols
239
 and protease
173
 may also affect digestion efficiency, therefore these 
factors must be evaluated to enable efficient signature peptide production. However, such 
studies are not frequently performed and the denaturation, reduction, alkylation and 
digestion (DRAD) protocol is not always optimized for protein of interest at low 
concentration.  
In this study, we aimed to develop an efficient DRAD protocol for brain derived 
neurotrophic factor (BDNF) at trace concentrations. BDNF is selected as the model 
protein for two reasons. First, BDNF is highly stable in structure, containing 70% β-sheet, 
20% β-turn240 and a cystine knot241. The protein exists as tightly folded homodimer in 
physiological condition, which is stable even in 8 M urea
240
. Exploration for an optimal 
DRAD protocol for BDNF may provide insights in developing signature peptide method 
for structurally related proteins, especially for the neurotrophin family. Second, BDNF is 
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an important neurotrophin that plays critical role in neuron cell survival, differentiation 
and neuronal plasticity
92
. Measuring in vivo concentration of BDNF can provide 
important information regarding location and mechanism of its modulation function in 
the living brain, however its extracellular concentration in the brain is low pM and 
challenging to measure
32,100
. Currently all BDNF in vivo detections are achieved by 
ELISA, which can reach LOD as low as 0.6-1 pM (mass LOD 60-100 amol). A signature 
peptide method with comparable LOD may serve as promising alternative for ELISA 
because of its potential in multiplexing.  
We conducted a systematic study to evaluate the enzyme selection, denaturing 
condition and enzyme concentration to achieve highly sensitive detection of BDNF. We 
discovered that chymotrypsin had higher signature peptide yield than trypsin; and 
immobilized chymotrypsin yielded better signature peptide signal than solution phase 
digestion. In addition, a preconcentration step during the denaturation, reduction and 
alkylation process was found to be necessary in yielding higher signature peptide signal. 
Combining all the optimization during the digestion and LC-MS analysis process, BDNF 
was able to be digested at 5 pM. When using the optimal DRAD protocol for BDNF, 
LOD was approximately 5 pM for BDNF, neurotrophin-3 (NT-3) and 10 pM for glial cell 
derived neurotrophic factor (GDNF) from 8 µL digest, correspsonding to 40-80 amol 
injected onto the column. This result shows that signature peptide method might be a 
promising alternative to ELISA to detect several low abundance neurotrophins from one 
sample fraction with high sensitivity.  
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4.2 Materials and methods 
4.2.1 Chemical and materials:  
Recombinant BDNF (rat, human, mouse, sequence MHSDPARRGELSVCDSISE 
WVTAADKKTAVDMSGGTVTVLEKVPVSKGQLKQYFYETKCNPMGYTKEGCRG
IDKRHWNSQCRTTQSYVRALTMDSKKRIGWRFIRIDTSCCTLTIKRGR), NT-3 (rat, 
human, mouse, sequence MYAEHKSHRGEYSVCDSESLWVTDKSSAIDIRGHQVTV 
LGEIKTGNSPVKQYFYETRCKEARPVKNGCRGIDDKHWNSQCKTSQTYVRALTS
ENNKLVGWRWIRIDTSCVCALSRKIGRT) and GDNF (rat, sequence MSPDKQAA 
ALPRRERNRQAAAASPENSRGKGRRGQRGKNRGCVLTAIHLNVTDLGLGYETK
EELIFRYCSGSCEAAETMYDKILKNLSRSRRLTSDKVGQACCRPVAFDDDLSFLD
DSLVYHILRKHSAKRCGCI) were from Peprotech (Rocky Hill, NJ). α-Chymotrypsin 
(from bovine pancreas, ≥40 units/mg protein), trypsin(from bovine pancreas, ≥10,000 
BAEE units/mg protein), dimethyl sulfoxide (DMSO), guanidine, urea, β-octyl-D-
glucopyranoside (BOG), iodoacetamide (IAM) and tris(2-carboxyethyl)phosphine (TCEP) 
were from Sigma-Aldrich (St Louis, MO). Immobilized chymotrypsin gel and 10× 
digestion buffer (1M triethylamine) was from Princeton Separations (Freehold, NJ). LC-
MS grade formic acid was from Fisher Scientific (Waltham, MA), LC grade ACN, 
MeOH and water were from Honeywell (Muskegon, MI), 5 µm Alltima C18 packing was 
from Grace Davidson (Columbia, Maryland) and fused silica capillary with 360 µm outer 
diameter (O.D.) was purchased from Molex (Lisle, IL).  
4.2.2 Protein denaturation and digestion 
Protein was dissolved in 10 µL artificial cerebrospinal fluid (145 mM NaCl, 2.68 mM 
KCl, 1.10 mM MgSO4,1.22 mM CaCl2, 0.50 mM NaH2PO4, and 1.55 mM Na2HPO4, pH 
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7.4) and concentrated to dryness using Eppendorf Vacufuge (Mt Laurel, NJ). 1 µL 
solution containing 0.02% BOG, 15 mM TCEP and 75 mM IAM was added to the vial. 
The vial was incubated in dark for 1 h with sonication to achieve denaturation, reduction 
and alkylation of the protein. The protein was then diluted with 18 µL digestion buffer 
containing 70% (v/v) 100 mM triethylamine (pH 8.0) and 30% (v/v) ACN. 1 µL solution 
containing free chymotrypsin (for solution phase digestion) or immobilized chymotrypsin 
with equivalent enzyme concentration to the free chymotrypsin (for chymotrypsin bead 
digestion) was added to the solution. The reaction was allowed to proceed overnight at 30 
o
C in a water bath (for solution phase digestion) or at room temperature on a rotary 
shaker (for chymotrypsin bead digestion), and quenched by addition of 0.5 µL 10% FA. 
The resulting supernatant from chymotrypsin bead digestion was transferred to a new vial 
and the digest was dried in vacufuge and re-suspended in 10 µL 0.5% FA for LC 
injection. 
4.2.3 Signature peptide LC-MS analysis 
The 75 µm inner diameter reverse phase capillary LC column and electrospray 
emitter tip assembly was made in-house with procedures detailed in our previous 
publications
19,38
. The column was connected to the LC-MS system which consisted of: a 
high pressure syringe pump (Teledyne Isco, Lincoln, NE) for fast sample loading; an 
Agilent 1100 HPLC pump (Santa Clara, CA) with flow-splitting for nano-flow elution; 
and two 6-port Cheminert  valves (Valco, Houston, TX ) switching between sample 
loading/injection and LC injection/elution. Mobile phase A (MPA) was 0.1% FA in water 
and mobile phase B (MPB) was 0.1% FA in MeOH.  The auto sampler (WPS-3000, 
Thermo Scientific) was incorporated with a 16 µL sample loop and operated at partial 
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loop mode. 8 µL of digest was injected directly to the analytical column with a program 
containing 4 min injection time and 2 min rinsing time. After injection the sample needle 
was washed by 100 µL wash solvent containing 50% MeOH, 50% water and 0.2% FA to 
prevent carry-over,  and peptides were eluted with the following gradient: 0.0-5.0 min: 
5%-95% MPB，5.0-10.0min: 95% MPB, 10.0-10.1 min: 95%-5% MPB, 10.1-13.0min: 5% 
MPB. Elution flow rate was 150 nL/min.  
The LC system was coupled to a linear ion trap (LTQ XL, Thermo Scientific) mass 
spectrometer operating at positive mode, and peptides were detected in MS/MS mode by 
collision induced dissociation. Detection was achieved with the following parameters: 
spray voltage = 2.0 kV, capillary temperature = 150 
o
C, automatic gain control (AGC) on, 
q = 0.25, isolation width = 3 m/z, activation time = 0.25 ms, number of micro scan = 1, 
normalized collision energy = 35%. 
To identify signature peptide, high concentration (500 nM) protein digest with 2:1 
protein-to-enzyme ratio was injected using the LC-MS set up and detected by data 
dependent “triple play” mode. Signature peptide was selected with the following criteria: 
(1) the peptide has good signal at both MS and MS/MS mode; (2) BLAST search against 
rodent data base shows that only the analyte protein contains the peptide sequence. The 
500 nM digest was also diluted by 0.5% FA to concentrations ranging from 100 pM to 2 
nM, and injected in triplicate to confirm that the selected peptide has good MS sensitivity 
and injection reproducibility at low concentration.    
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4.3 Results and discussion 
4.3.1 Selection of protease for signature peptide production 
In initial digestion experiment using trypsin, fragment ALTMDSK and TTQSYVR 
were selected as potential signature peptide according to the criteria described in the 
experimental session. Injection of 100 pM digest gave no signature peptide signal, 
although injection of diluted high concentration tryptic digest confirmed detection of 
these peptides at 100 pM (Figure 4.1A). This indicated that the poor signal of tryptic 
signature peptide came from low peptide yield of the digestion reaction at low 
concentrations, not the low LC-MS sensitivity of these peptides. In contrast to tryptic 
peptides, a peptide fragment produced by chymotrypsin digestion showed good signal 
when BDNF was digested at 100 pM (Figure 4.1A), therefore chymotrypsin was selected 
as protease for BDNF signature peptide method. The MS
2
 spectrum of the chymotryptic 
peptide EKVPVSKGQLKQY is in Figure 4.1B.  
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Figure 4.1 Selection of protease for BDNF digestion. (A) Overlaid reconstructed ion chromatogram (RIC) 
of tryptic peptide ALTMDSK and TTQSYVR and chymotryptic peptide EKVPVSKGQLKQY when 100 
pM BDNF digest was injected.  BDNF was digested at 100 pM (red chromatograms and blue 
chromatogram) or digested at 500 nM then diluted to 100 pM (black chromatograms). MS/MS pathway for 
ALTMDSK was: 383.43 ([M+2H]
2+
) 234.15 (y2),514.36(b5-H2O), 581.28 (y5); for TTQSYVR was: 
427.65([M+2H]
2+
)418.96(b4), 524.28 (y4), 652.42(y5).  (B) MS2 spectrum of chymotryptic peptide 
EKVPVSKGQLKQY.  
The poor tryptic signature peptide yield could be associated with the tightly folded 
homodimer structure of BDNF
240
. This could have potential impact on the accessibility of 
cleavage site to protease, and eventually on the yield of certain peptide fragment. 
Visualization of the structure of a dimer protein containing BDNF (visualization tool: 
PyMol, protein ID: 1bnd) reveals that its potential tryptic signature peptides sequences all 
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locate in the β-turn structure, while the chymotryptic peptide sequence is in a region 
containing mostly random coil, which can possibly explain our observation that 
chymotrypsin digestion resulted in much higher signature peptide signal.  
4.3.2 Evaluation of denaturing condition 
Protein denaturation is necessary to achieve complete digestion and the optimal 
denaturing condition is protein-dependent
177
. Denaturation can be achieved by using high 
concentration chaotropic agents such as 6 M guanidine and 8 M urea
242,243
, or surfactant 
such as sodium dodecyl sulfate (SDS)
177
, or organic solvent such as ACN and 
MeOH
244,245
. Denaturation is followed by reduction of disulfide bond and alkylation of 
free cysteine using reducing and alkylation reagents such as TCEP and IAM. The 
resulting protein solution requires either extensive dilution or clean-up to reduce the 
concentration of denaturant to preserve protease activity. However, the dilution and 
clean-up procedures are not favored in low-abundance protein digestion because of even 
lower digestion rate
238
 and potential protein loss during the clean-up procedure. 
Alternatively, protein can be unfolded by heat which does not introduce additional 
denaturant that compromises protease activity
179
.  In many low abundance protein-
signature peptide studies, proteins are also digested directly without denaturation
246
.  
Based on these considerations, we initially tested four different denaturing conditions 
on 100 pM BDNF dissolved in 10 µL aCSF: (1) direct digestion without denaturing the 
protein; (2) digestion after heating the protein at 90 
o
C for 1 h; (3) digestion after heating 
the protein with the presence of TCEP and IAM at 90 
o
C for 1 h; (4) denaturing, reducing 
and alkylating dried protein in 1 µL 0.02% BOG containing TCEP and IAM and diluting 
it to 20 µL for digestion. In all the four conditions, protein concentration during digestion 
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were kept at 50 pM (1:1 dilution of starting protein standard) to eliminate possible impact 
of protein concentration on digestion efficiency.  
Figure 4.2 A shows that directly digesting protein without denaturation step produced 
signature peptide, while heating the protein did not help in increasing its signal, and the 
presence of TCEP and IAM in the heat-denatured sample dramatically decreased 
signature peptide signal. This could be due to chymotrypsin deactivation when high 
concentration of TCEP and IAM were still in the digestion mixture, or IAM modification 
of BDNF at active sites such as lysine or glutamic acid of the signature peptide 
sequence
247
, which can result in different peptide mass. Concentrating BDNF before 
denaturation and then diluting it for digestion produced significantly higher (F=40.686, 
P<0.0001, one way ANOVA test) signature peptide signal. This may be attributed to the 
high concentrations of TCEP and IAM during the denaturation, reduction and alkylation 
step which could effectively reduce and alkylate BDNF to prevent it from refolding, and 
their lower concentration during the digestion step which maintained chymotrypsin 
activity. Therefore, in subsequent experiments, 10 µL of BDNF solution was first 
concentrated to 1 µL for denaturation, reduction and alkylation, followed by dilution to 
20 µL for digestion.  
In addition to 0.02% BOG, we also tested 0.1% BOG, 6M guanidine and 93% DMSO 
as denaturants. BOG is a non-ionic surfactant that is used to solubilize membrane 
protein
248. It is technically “non-denaturing” but previous study had used it in 
combination with sonication to dissolve protein prior to reduction and alkylation
249
 for 
signature peptide method using chymotrypsin. 6 M guanidine was reported to fully 
unfold BDNF while 8 M urea failed to
240
. High concentration DMSO was also reported 
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to be able to fully unfold protein
250
. 1 µL mixture containing one of the above 
denaturants, 15 mM TCEP and 75 mM IAM was used to redissolve dried BDNF solution 
for denaturation. Results showed that 0.1% BOG and 93% DMSO gave comparable 
signature peptide signal to 0.02% BOG; however, with bigger signal variation. 
Surprisingly, 6M guanidine gave the lowest signature peptide signal. Removing 
guanidine by extracting the protein using C18 spin column prior to digestion partially 
restored the signature peptide signal. Therefore the low signature peptide signal could be 
due to residual guanidine in the digestion mixture which either caused matrix effect or 
deactivated chymotrypsin. Compared to the protein samples to which no denaturant was 
added, 0.02% BOG did not yield significantly higher signature peptide signal (unpaired t-
test, p = 0.1623). The statistical insignificancy may origin from the small replicate 
number of each denaturant (n = 4) and large relative standard deviation within each group 
(34% for 0.02% BOG, 61% for no denaturant group). Based on the fact that 0.02% BOG 
gave 70% higher averaged peak area, it was selected as denaturant for the following 
experiments.  
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Figure 4.2 Evaluation of denaturation condition. (A) Selection of denaturation protocol for 10 µL protein 
standard containing 100 pM BDNF. 1: BDNF digested directly without denaturation. 2: BDNF denatured 
by heating at 90 
o
C for 1 hour. 3: BDNF denatured by heating with 10 mM TCEP and 50 mM IAM at 90 
o
C 
for 1 hour. 4: BDNF dried and dissolved in 1 µL buffer containing 0.02% BOG, 15 mM TCEP and 75 mM 
IAM, sonicated in dark for 1 h and then diluted to 20 µL for digestion. 6 replicates were digested and 
injected for each condition.  (B). Selection of denaturant using protocol 4, 15 mM TCEP and 75 mM IAM 
was dissolved in 0.02% BOG, 6M guanidine, 0.1% BOG, 93% (v/v) DMSO, or water to re-dissolve the 
dried protein standard. 4 replicates were digested and injected for each denaturant. The final solution pH 
for digestion was checked before addition of chymotrypsin to make sure it is approximately 8.0.  
4.3.3 Effect of enzyme concentration 
In our initial investigation, 100 pM BDNF was reduced and alkylated and then diluted 
to 50 pM by adding chymotrypsin at a final concentration of 1 nM (enzyme: protein = 
20:1). We compared the effect of adding chymotrypsin at once at the beginning of 
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digestion or every 8 hours for a total of 24 h. Although the final enzyme concentration 
was 1 nM in both procedures, adding fresh aliquot every 8 hours produced signature 
peptide signal that was 3 times higher (Figure 4.3A). This result indicates that 
chymotrypsin might have been deactivated before most BDNF molecule was digested, 
and supplementing the digestion mixture with fresh enzyme helped to continue the 
reaction. Adding fresh enzyme every 8 hours can be laborious, therefore other options 
were also explored, including higher chymotrypsin concentration
238
 and chymotrypsin 
immobilized on beads since the immobilized enzyme has higher local concentration on 
the bead surface. As shown in Figure 4.3A, a 100:1 enzyme-to-protein ratio gave 2 times 
higher signal and immobilized chymotrypsin showed 3.5 times increase in signal. Since 
the equivalent enzyme concentration was still 1 nM in the immobilized chymotrypsin 
procedure, the enhancement in signature peptide production is likely related to the higher 
local enzyme concentration that resulted in more complete BDNF digestion before 
chymotrypsin was deactivated.  
The effect of chymotrypsin bead concentration on the signature peptide signal was 
also studied by varying chymotrypsin bead concentration from 20 pM to 50 nM in 50 pM 
protein standard (enzyme to protein ratio from 0.4:1 to 1000:1) and evaluating the 
resulting signature peptide signal. This experiment revealed that the signature peptide 
signal leveled off above 2 nM chymotrypsin (equivalent to free concentration), 
corresponding to a 40:1 enzyme-to-protein ratio (Figure 4.3B). A slight decrease of signal 
at chymotrypsin bead concentration higher than 2 nM was attributed to production of a 
high concentration of chymotrypsin autolysis fragment KIAKVF (m/z=353.54) which co-
eluted with signature peptide and suppressed its signal (Figure 4.3C).  
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Figure 4.3 Determination of chymotrypsin concentration. (A) Impact of chymotrypsin format on signature 
peptide signal. 1: 5 nM chymotrypsin, solution phase digestion; 2: 1 nM chymotrypsin, solution phase 
digestion; 3: Adding 0.33 nM chymotrypsin every 8 hours to a total of 1 nM chymotrypsin; 4. 
chymotrypsin bead, equivalent enzyme concentration=1 nM. 4 replicates each chymotrypsin format (B) 
Impact of chymotrypsin bead equivalent concentration on signature peptide signal. 4 replicates each bead 
concentration. (C) Chromatogram comparison of 2 nM chymotrypsin bead digest and 50 nM chymotrypsin 
bead digest. Signature peptide was monitored at MS
2  
full scan mode, base peak chromatogram (BPC) was 
recorded with MS full scan mode.  
4.3.4 Codigestion with NT-3 and GDNF 
One advantage of signature peptide method over immunoassay is its ease in realizing 
multiplexed detection. Therefore, NT-3 and GDNF was selected in this study to 
determine if they can be co-digested with BDNF at low concentration. NT-3 and GDNF 
are members of neurotrophin family and play important role in promoting the growth and 
differentiation of neurons
251-253
. They are also structurally similar to BDNF, being 
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homodimers containing predominantly β-sheet structure and cystine knot241,254. Injection 
of digested protein standard containing BDNF, NT-3 and GDNF (100 pM each) showed 
that NT-3 produced similar signature peptide signal to that of BDNF, while GDNF’s 
signature peptide signal was 10 times lower (Figure 4.4). This could be due to the fact 
that GDNF’s dimer is linked by covalent disulfide bond, therefore it is more difficult to 
unfold, causing lower signature peptide yield.  
 
Figure 4.4 RIC and base peak (BP) intensity of BDNF, NT-3 and GDNF’s signature peptide when the 
three proteins were digested together. Protein concentration: 100 pM each. NT-3 signature peptide: 
VTDKSSAIDIRGHQVTVL, MS
2
 pathway: 485.97 ([M+4H]
4+
)564.63([b16-H2O]
3+
), 597.49([b17-
H2O]
3+
), 603.51(b17
3+
);GDNF signature peptide: DKILKNL, MS
2 
pathway: 422.39([M+2H]
2+
) 
487.35(y4), 583.00(y5-NH3), 600.32(y5) . 
4.3.5 Method sensitivity 
The signature peptide signal response over concentration change was studied by 
injecting 8 µL digest produced from 100 pM to 2 nM protein. Resulting calibration 
curves showed good linearity (Figure 5A) and sample-to-sample reproducibility.  LODs 
were estimated to be ~4 pM for BDNF, 4 pM for NT-3 and ~9 pM for GDNF. 5 pM 
BDNF and NT-3 or 10 pM GDNF were also digested and analyzed to confirm the 
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presence of signature peptide signal at calculated LOD (Figure 5B). This corresponds to 
50 amol BDNF, NT-3 or 100 amol GDNF in the starting protein standard, and 40 amol 
BDNF, NT-3 or 80 amol GDNF injected onto the column. Further improvement in 
reproducibility and quantification can be achieved by including isotopically labeled 
signature peptide internal standard to reduce the variability introduced after digestion.  It 
is also worth noting that the signature peptides were injected with no addition of ACN 
because they had no observed carry-over when injected in aqueous solution and addition 
of ACN, even to 5%, decreased signature peptides’ signal.  
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Figure 4.5 Signature peptide method sensitivity for BDNF, NT-3 and GDNF. (A) Calibration curve of 
BDNF, NT-3 and GDNF using signature peptide produced by digesting these proteins together. 3 replicate 
digestion each concentration. (B) RIC of signature peptides at concentration close to LOD. GDNF: 10 pM 
protein digested; NT-3 and BDNF: 5 pM protein digested. LOD was estimated using equation LOD=blank 
signal+3×standard deviation of blank signal. 
4.4 Conclusion 
In this chapter, we have developed a signature peptide method for detecting BDNF. 
Our investigation revealed that in the case of BDNF, chymotrypsin had better signature 
peptide yield than trypsin, and a concentration step prior to denaturation, reduction and 
alkylation was necessary for improved signature peptide’s yield of this structurally stable 
protein. In addition, immobilized chymotrypsin bead was shown to result in higher 
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signature peptide yield. The result had shown necessity of optimizing DRAD protocol of 
a signature peptide method for structurally stable protein. The selection of enzyme, 
denaturation condition and enzyme format all affected signature peptide production. With 
all the optimized digestion procedure for BDNF, NT-3 and GDNF could be co-digested 
and detected at mid-amol level. Combining with protein purification, this method may be 
a potential alternative to immunoassay to achieve sensitive detection of several 
neurotrophins from one sample.  
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Chapter 5  
 
Conclusions and future directions 
 
In this dissertation, the analytical performance of cLC-MS in neuropeptide detection 
was improved in terms of speed and sensitivity. The detection speed was enhanced by 
utilizing 10 µm particulate phase as packing material in a 75 µm bore capillary column. 
The larger particle diameter and column I.D. compared with previously reported 25 µm 
bore column packed with 5 µm particle has greatly reduced column backpressure during 
sample injection and rinsing; therefore, enabling faster sample injection under the same 
injection pressure. A fast injection flow rate (14 µL/min) combining with low elution 
flow rate (100 nL/min) was determined to be the optimal for fast sample analysis (4 
min/sample compared to previously reported 20-30 min /sample) while still maintaining 
low LOD of 3 pM for LE, ME and 10 pM for DynA1-8 from a 5 µL standard. This method 
was validated for in vivo detection of LE and ME from rat GP.  
In terms of sensitivity improvement, we have discovered that the poor LC-MS 
response of certain big neuropeptides such as β-endorhpin, orexins and Gal can be 
attributed to its adsorption loss to surfaces prior to being injected onto LC column. ACN 
was added to sample to prevent adsorption loss and improve sensitivity. Since increased 
ACN percentage could result in both reduced adsorption loss and lower peptide retention 
during injection, an optimal ACN percentage that yielded highest peptide signal was 
determined for each of 10 tested peptides. The optimal ACN percentage had positive 
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correlation with peptide molecular weight and retention time on a reverse phase column. 
This method was applied to 10 neuropeptides. LOD was improved by as much as 60 fold 
and were consistently 0.1-2 pM from 8 µL sample for all neuropeptides tested.  
This work also improved in vivo recovery of neuropeptides by microdialysis. 
Hydrophilic, negatively charged microdialysis probe membranes were modified with 
polycationic PEI to reduce electrostatic interaction between positively charged peptides 
and the membrane. The modification significantly improved recovery of 7 out of 11 
neuropeptides tested. All peptides that were improved had net positive charge at 
physiological pH illustrating the significance of charge for affecting recovery.  
The ACN addition method combined with PEI modification was applied for detecting 
intact orexin A (MW 3561) and orexin B (MW 2936) from rat arcuate nucleus. This 
study was the first in vivo monitoring of orexin A using mass spectrometry, and first in 
vivo monitoring of orexin B. In this same experiment a peptide fragment from an un-
reviewed rat POMC that has identical sequence as mouse β-endorphin was also identified 
and detected. This result illustrates the high sequence specificity of MS detection. 
Together the results show that this combined approach enables in vivo detection of 
previously difficult to detect neuropeptides. 
In addition to these neuropeptides, we also developed a high sensitivity signature 
peptide method capable of detecting BDNF and related proteins. These proteins proved 
challenging to detect because of their low concentration and stable structures that resist 
ordinary digestion conditions. We discovered that chymotrypsin digestion produced a 
signature peptide that could be reliably detected at pM level, while trypsin failed to 
produce such signature peptide due to incomplete digestion. Besides, a concentration step 
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prior to protein denaturation, reduction and alkylation was found to be necessary for 
achieving high signature peptide signal. We also found that immobilized chymotrypsin 
bead produced higher signature peptide signal, even at the same equivalent enzyme 
concentration.  We were able to utilize the digestion protocol optimized for BDNF for co-
digesting other 2 structurally similar neurotrophins, NT-3 and glial GDNF. This method 
has 5 pM LOD for BDNF and NT-3 and 10 pM LOD for GDNF from 8 µL protein 
standard digest, displaying potential in realizing highly sensitive, multiplexed 
quantification for neurotrophin. 
Future directions based on this dissertation can include both method development and 
application in biological studies. The improvement in analytical speed and sensitivity in 
this dissertation can be applied to develop high performance method for other peptides 
for their in vivo applications. Also further method development that overcomes current 
limitation could also be an important direction.  
5.1 ACN addition for improving sensitivity of other big neuropeptides  
Adding ACN effectively reduced adsorption loss and allowed high detection 
sensitivity by cLC-MS for several larger neuropeptides such as orexins, β-endorphin and 
Gal that had previously been difficult to detect. This can be potentially extended to 
detecting other biologically important, large neuropeptides. One example is glucagon, 
which can be detected at 500 pM when injected without ACN addition (Figure5.1).  
Glucagon showed good MS intensity when directly infused to an ion trap MS (Figure 
5.1 A, B), the signal intensity was comparable to that of LE, which had 0.5-3 pM LOD 
detected by cLC-MS . However when injecting glucagon onto the same cLC-MS system, 
the lowest detectable concentration was 500 pM. The good MS response under direct 
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infusion has suggested that the poor cLC-MS signal could either originate from LC 
tubing or container vials. Further investigation showed that blank aCSF injection after 
injecting 5 nM glucagon gave 4 times higher signal than the standard injection, indicating 
adsorption loss in the LC tubing was a substantial cause for the low cLC-MS signal. 
In addition to glucagon, studies in the past 5 years also reported LC-MS detection of 
other large neuropeptides from biological samples, including parathyroid hormone1-34 
(PTH, 4118 Da)
144
, salmon calcitonin  (3432 Da)
148
, Apelin-36 (4196 Da)
149, Aβ38 (4132 
Da)
146,147
, Aβ40 (4330 Da)
 146,147 
 and  Aβ42  (4514 Da)
145-147
. Concentration LOD as low as 
3 pM, 11 pM and 12 pM was achieved for salmon calcitonin
148
 , Aβ42
145-147
 and Apelin-
36
149
, showing possibility for detecting neuropeptides even larger than orexin A (3561 Da) 
documented in this dissertation.  Although mass LOD was still at mid-to-high fmol range, 
the sensitivity could potentially be improved by utilizing a capillary column and ACN 
addition to minimize adsorption loss.  
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Figure 5.1 LC-MS analysis of glucagon standard without ACN addition. (A) MS
1
 spectrum of 10 µM 
glucagon directly infused into LCQ Deca XP Plus. Glucagon was dissolved in 50% MeOH, 50% H2O with 
0.1% FA. (B) MS/MS spectrum of glucagon, mother ion m/z 871.78. (C) MS
2 
of 500 pM glucagon injected 
onto a 50 µm Altima C18 column, injection volume: 5 µL, glucagon standard was dissolved in aCSF with 
0.5% FA. 
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In this dissertation we have demonstrated in vivo detection of intact orexins. 
Therefore another possible project in this direction is to develop methods for orexin 
fragments. Since current method has good sensitivity for intact orexins, and the optimal 
ACN% correlates with molecular weight, we expect the optimal ACN% for orexin 
fragments to be lower than 25%. In addition, since smaller peptides are less prone to 
adsorption loss, we also expect orexin fragments to have higher microdialysis recovery. 
The method for orexin fragments could be applied to determine the biologically active 
form for future in vivo studies and to understand the in vivo processing of orexins.  
5.2 Developing fast detection method for more neuropeptides 
In chapter 2, we demonstrated that a 75 µm bore column packed with 10 µm particle 
was able to maintain good sensitivity and low pM LOD for enkephalins and DynA1-8 with 
4min/sample analysis rate. The method could be further applied for improving analysis 
speed for other neuropeptides with established cLC-MS method. For example, the time 
needed for analyzing 8 µL sample in chapter 3 using a 75 µL column packed with 5 µm 
particle was 17 min (2 min sample loading into auto sampler+3 min sample injection+2 
min sample rinsing+10 min elution), resulting in a total of 12 h analysis time for a regular 
in vivo experiment (3 animals, 10 fractions/animal plus 4 point calibration curve, 3 
replicates). If the fast preconcentration method could be applied with similar turn-over 
rate reported in chapter 2 (4 min/sample), these samples could be analyzed within 3 h 
instead of 12 h. Chapter 2 also provides some useful guidance on developing fast analysis 
method from an established, sensitive but “slow” cLC-MS method. First of all, evaluation 
of the impact of particle size on sensitivity should be performed by comparing peptide 
signal on a column packed with regular 5 µm material and 10 µm material. This is 
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because larger particle size may possibly lead to worse separation efficiency and broader 
peaks, which can compromise sensitivity.  Second, optimal injection flow rate should be 
identified using the column packed with 10 µm particles. The optimal injection flow rate 
should be the highest injection flow rate without peptide signal decrease. For enkephalins 
and DynA1-8 injected in aCSF this flow rate was 14 µL/min; however, the value may vary 
with peptides due to differences in hydrophobicity and content of ACN in the sample.  
Another option for improving speed while maintaining good separation is to utilize a 
monolithic column. Monolithic columns are known for improved separation efficiency at 
reduced back pressure comparing to packed columns. Polymer monoliths are easier to 
make, and can potentially be patterned into a microfluidic device by photo-initiated 
polymerization. However this type of column failed to retain peptides when injection 
flow rate exceeded 0.8 µL/min (Appendix 2), due to its intrinsically low surface area (20-
30m
2
/g) and lack of meso pores. Silica monolithic column are more challenging to 
fabricate; however, they contain both macro pores and meso pores, and are suitable for 
retaining small molecules and peptides. Commercial silica monolithic column with C18 
surface functionality (Chromolith
TM
, Merck Millipore) can achieve 300 m
2
/g  surface 
area and carbon load as high as 18% , compared  to 200 m
2
/g  and 12% for Alltima C18 
used in this dissertation. Therefore silica monolith can serve as potential alternative for 
large particulate phase for fast neuropeptide preconcentration and analysis with good 
separation efficiency.  
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5.3  Improving microdialysis probe recovery for higher peptide detectability from 
the brain 
As discussed in Chapter 3, enhancement in probe recovery was achieved by PEI 
modification on an in-house constructed AN69 probe. The modification significantly 
improved recovery for 7 out of 11 neuropeptides, achieving ~10% recovery for most 
large neuropeptides carrying four net positive charges. However, the recovery for orexin 
A was still low (~0.2%). Orexin A carries +1.2 net positive charge at pH 7.4 and has 
similar size to other better-recovered neuropeptide, such as β-endorphin. The low 
recovery might still origin from orexin adsorption to the microdialysis catheter, indicating 
PEI modification did not fully eliminate active sites for adsorption. The slow probe 
response in Chapter 3 also supports this hypothesis; therefore the probe modification 
protocol needs further optimization to eliminate peptide adsorption. One possible 
direction is to investigate the influence of different PEI format on peptide relative 
recovery. PEI is available in linear and branched format, with average molecular weight 
ranging from ~1 kDa to 750 kDa. While chapter 3 only tested one PEI (branched, MW 
2kDa), other PEIs might be more strongly bound to the negatively charged surface and 
provide better blockage of negatively charged sites.  
The probes used in this dissertation were manually constructed in-house with fused 
silica capillary, AN69 membrane, stainless steel tubing, epoxy gel and superglue, and the 
peptide-containing dialysate was in contact with all of the components in its flow path.  
The complex chemical property of these surfaces may indicate other adsorption 
mechanism, such as hydrophobic interaction and hydrogen bond in addition to 
electrostatic interaction. Further blockage of adsorption site could potentially be achieved 
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by introducing inert functional groups, such as polyethylene oxide (PEO) to the surface, 
and one possible yet simple approach was to flow Pluronic F-127 (PEO98-PPO67-PEO98)
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or poly L-lysine-PEO
255
 through the entire microdialysis catheter including the probe. 
Pluronic F-127 blocks hydrophobic surface by adsorption of the hydrophobic block 
polypropylene oxide (PPO), while leaving hydrophilic PEO chain forming a water-
swelling layer that repels proteins from the surface.  This polymer has been applied for 
modifying microdialysis probe to improve protein recovery
103
. Poly L-lysine-PEO 
adsorbs to negatively charged surface by electrostatic interaction between the surface 
charge and poly-L-lysine chain grafted to PEO, although this method has not been 
applied to microdialysis yet, it reduced adsorption of serum protein on a surface grafted 
with negatively charged peptide RGD
255
 and therefore can potentially be applied for 
modifying AN69 probe.  
Another possible direction was to improve fabrication protocol to create probe 
scaffold and membrane that are less prone to absorbing peptides/proteins. Our group has 
previously reported microfabricated push-pull probe from silicon wafer by lithography 
and bulk machining
256
. The resulted interior surface of the probe channel was a 3 µm 
layer of polysilicon, in contrast to the complex inner surface composition of a regular 
microdialysis probe. This fabrication process is also being applied by our group for 
constructing microdialysis probes. Although the focus of the on-going study is to develop 
micro-scale microdialysis probe for improved spatial resolution and reduced tissue 
damage, it will be interesting to investigate the adsorption property of the microfabricated 
dialysis probe and see if the more uniform probe inner surface can either reduce peptide 
adsorption loss or be easily modified to generate peptide/protein repelling surface.  
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In addition to reducing adsorption loss onto the microdialysis catheter, sampling 
recovery could also be improved by increasing neuropeptide mass transport into the 
microdialysis probe. As discussed in Chapter 1, affinity enhanced microdialysis can be 
applied for neuropeptide detection. Potential issue with affinity enhanced microdialysis is 
the high level of affinity agent in dialysate that can possibly interfere with LC-MS 
detection. Besides, bead saturation, settling and clogging also needs to be evaluated for 
methods using immobilized affinity agents. Future projects in this direction could include 
feasibility study of incorporating affinity agent (free form or immobilized on bead) into 
microdialysis perfusion media.  
5.4 Improving signature peptide method for detecting BDNF from biological sample 
Chapter 4 has discussed the development of a sensitive signature peptide method for 
BDNF. The study provided insight into BDNF’s resistance to protease digestion and gave 
solutions for overcoming the obstacle in digesting this protein, future projects could 
continue into testing the method for detecting BDNF from biological samples such as in 
vivo dialysate and CSF. The protein content in dialysate is much lower than that in CSF, 
therefore dialysate may be less likely to have interference issue caused by high 
abundance protein, and additional sample cleanup before digestion might not be crucial 
for dialysate analysis. Including a SIL internal standard for the signature peptide may be 
necessary for correcting matrix effect in MS analysis and estimating the signature peptide 
production efficiency at low concentration.  In addition, the current method involves two 
solution drying steps (concentrating the protein for denaturation, reduction and alkylation 
and removing ACN from the final digest. ACN was added to the immobilized 
chymotrypsin digestion mixture to prevent BDNF and signature peptide adsorption loss 
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to the container vial and the beads) and multiple pipetting steps. For practical 
considerations of biological studies which easily generate 20-30 samples per day, future 
projects can also be directed to improving digestion protocol to reduce the amount of 
labor involved. Possible ideas include processing sample using multichannel pipette in 96 
well format, or use microwave
257
 or ultrasound irradiation
258
 to facilitate BDNF digestion 
without requiring denaturation prior to digestion. Previous study has shown that 
microwave-enhanced trypsin digestion could produce signature peptide from 17 pM N-
terminal prohormone of brain natriuretic peptide within 50 min. Therefore it will be 
valuable to study if these irradiation formats could potentially enhance BDNF digestion 
without requiring extensive denaturation.  
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Appendix A  
 
Signature Peptide and Microchannel ELISA Methods for Measuring Biochemical 
Indicators of Implantation Success of Tissue-Engineered Oral Mucosa 
 
A.1 Objective 
Develop fast and sensitive analytical method for quantifying ultra-low level protein 
markers in EVPOME spent medium within 2-3 hours to provide assessment on EVPOME 
viability prior to implantation.  
A.2 Approach #1: Signature peptide method for simultaneous quantification of two 
protein markers 
A.2.1 Experiment 
A.2.1.1 Protein digestion using trypsin immobilized bead 
Recombinant human IL-8 and VEGF (carrier free, R&D systems) was dissolved in a 
buffer containing 40% (v/v) ACN and 60%(v/v) 100 mM phosphate buffer saline (PBS, 
pH 2.5) and serially diluted with the buffer to form standard with concentration ranging 
from 10 pM to 10 nM. 10 µL protein standard was aliquoted to a 500 µL protein LoBind 
centrifuge tube (eppendorf), and 0.5 µL 200 mM TCEP (Sigma-Aldrich), 0.5 µL 1M 
IAM (Sigma-Aldrich) were added, 2 µL 1M Tris buffer  was also added to adjust solution 
pH to ~8.0. The reaction was allowed to be incubated in dark under room temperature for 
1 h to allow reduction and alkylation of disulfide bonds in IL-8 and VEGF. Then 2.5 µL 
200 mM DTT was added and incubated for 40 min to react with the residue IAM, and the 
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reaction mixture was diluted to 25 µL with 2.5 µL 50 mM ammonium bicarbonate (pH 
8.0) and 8 µL ACN. 5 µL immobilized trypsin magnetic bead slurry (Clontech, 500 µL 
bead slurry was washed by water for 5 times, and excessive supernatant was removed to 
form ~50 µL 10 ×concentration bead slurry) was added to the protein solution. The 
reaction was allowed to incubate on a rotary shaker under room temperature for 2.5 h. 
The ACN% in the reaction mixture was 40% to prevent protein from sticking to the 
magnetic bead.  After 2.5 h the resulted digest was quenched by 0.5% FA and supernatant 
was separated from the bead by a magnet, dried in a vacufuge and reconstitute in 10 µL 
0.5% FA for LC-MS injection.  
A.2.1.2 cLC-MS analysis of signature peptides 
The cLC-MS system set up and MS detection was detailed in chapter 3 and chapter 4, 
except that mobile phase B (MPB) was ACN with 0.1% FA. 5 µL reconstituted digest 
was injected directly under full loop mode onto a 50 µm I.D. column packed with 5 µm 
Alltima C18 particle to 6 cm. The injection pressure was 4000 psi, the digest was injected 
for 8 min and washed by loading solvent for another 4 min.  Gradient for elution was: 0-1 
min: 0%-10% MPB, 1-16 min: 10%-50% MPB, 16-18 min: 50%-95% MPB, 18-21 min: 
95% MPB, 21-21.1 min: 95%-0% MPB, 21.1-23 min 0% MPB.  
A.2.1.3 Immunoaffinity capture of IL-8  
The immunoaffinity column (180 µm I.D.) was packed in house to 5 cm with 
immobilized antiIL-8 particle (Nucleosil silica support, 7 um diameter, 300 Å pore size) 
provided by group colleague, Dr. Michelle Johnson. To capture IL-8, 500 µL solution 
(100 mM PBS, pH 7.0) containing 500 pM IL-8 as target protein and 26 nM VEGF as 
interfering protein was loaded onto the column. The column was washed by pH 7.0 PBS 
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at 7 µL/min to remove unbound protein, and the flow-through was collected every 3 min 
for a total of 15 minues (5 fractions). Then the elution buffer (100 mM PBS, pH 2.0) was 
pumped through the column at 7 µL/min to release captured IL-8. The flow-through was 
collected every 3 min for a total of 18 min (6 fractions). All the collected fractions were 
digested with immobilized trypsin according to the protocol described above.  
A.2.2 Result 
A.2.2.1 Signature peptide for IL-8 and VEGF 
 
Figure A.1  MS
2
 spectra of signature peptide of IL-8 and VEGF. (A) MS
2
 spectrum of signature peptide 
TYSKPFHPK for IL-8, parent ion was [M+3H]
3+
 (m/z 369.0). (B) MS
2 
spectrum of signature peptide 
HLFVQDPQTCK for VEGF, parent ion was [M+2H]
2+
 (m/z 687) 
A.2.2.2 Higher signature peptide production and fast digestion achieved by 
immobilized trypsin 
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Figure A.2 Immobilized trypsin digestion showed better signature peptide yield than solution phase 
digestion. (A) Overlaid RIC of IL-8 signature peptide TYSKPFHPK produced from overnight solution 
phase digestion at 37 
o
C (black curve) and 2.5 h immobilized trypsin bead digestion at room temperature 
(red curve). IL-8 concentrations in both cases were 10 nM, reduction and alkylation protocol used were 
identical. (B) IL-8 signature peptide signal reached maximum after immobilized trypsin digestion for 2.5h, 
and remained stable after 18.5h.  IL-8 concentration was 10 nM and 3 replicate digestions were analyze for 
each time point.  
A.2.2.3 RIC for IL-8 and VEGF at lowest detectable concentration 
 
Figure A.3 RIC of IL-8 signature peptide TYSKPFHPK and VEGF signature peptide  HLFVQDPQTCK at 
lowest detectable concentration. The lowest detectable concentration for IL-8 was 10 pM, and for VEGF 
was 200 pM. Injection volume was 5 µL.  
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A.2.2.4 Combining with immunocapture to preconcentrate IL-8  
 
Figure A.4 IL-8 and VEGF signal profile when loading the proteins onto an anti IL-8 column.  
A.2.3 Discussion 
The digestion time for this method was 2.5 h compared with conventional solution 
phase overnight digestion, which may potentially fulfill the goal of fast and sensitive 
protein marker quantification. This approach was not applied for actual detection of IL-8 
and VEGF from EVPOME spent medium due to several reasons. First, the antibody 
column we used showed non-specific binding problem. VEGF (26 nM) was 52 times 
more concentrated than IL-8 (500 pM) in the solution prior to IL-8 immunoaffinity 
capture, and after capture, the signal of VEGF’s signature peptide in eluent was over 100 
times higher than IL-8’s signature peptide signal, suggesting the column was non-
selectively binding VEGF while the antibody was targeting IL-8. Second, although 
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digestion time can be reduced to 2.5 h, the time needed for reduction, alkylation (1h 40 
min), solution drying (50 min) and LC-MS analysis (40 min) still resulted in an overall 
analysis time of >5 h.  The cLC-MS method developed in Chapter 2 may apply here to 
improve analysis speed, however highly sensitive and faster sample preparation that 
produces signature peptide ready for injection within less than 2 hours needs to be 
developed. Shorten reduction, alkylation time needs to be tested to determine if signature 
peptide signal is unaffected, and shorter digestion time can be potentially achieved by 
testing digestion time points between 0.5-2.5 h, or employing microwave or ultrasound 
irradiation to enhance digestion speed, as discussed in chapter 5. In addition, commercial 
kits such as Flash Digest (Perfinity Biosciences, West Lafayette, IN) can be potentially 
useful in increasing digestion speed. Such kits utilize immobilized, high temperature-
stable trypsin to achieve complete digestion of protein at protein denaturing temperature 
(70 
o
C) within 1-30 min, eliminating the need for protein denaturation, reduction and 
alkylation.  
A.3 Appoach #2: Microchannel ELISA method for quantifying protein markers in 
EVPOME spent medium.  
A.3.1 Experiment  
For microchannel ELISA, Optimser™ microfluidic ELISA plate assembly, buffers, 
and reagents were from Siloam Biosciences (Cincinnati, OH). IL-8 and VEGF antibody 
pairs were from Life Technologies (Carlsbad, CA). Human β defensin-1 (hBD-1) and 
tissue inhibitor of metalloproteinases -1 (TIMP-1) reagent kits were from Peprotech 
(Rocky Hill, NJ). The TIMP-2 antibody pair was from R&D Systems (Minneapolis, MN). 
The optimized conditions and LODs for microchannel ELISA measurement are listed in 
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Table A.1. Measurement was conducted according to the protocol provided by Siloam 
Biosciences, except for the TIMP-1 assay, whose optimal wash was 0.05% Tween-20 in 
PBS (pH 7.0). The protein concentration was measured in triplicate based on external 
calibration.  
Table A.1 Optimized ELISA condition and LOD of each protein marker 
Protein 
marker 
Coating buffer Capture antibody 
concentration 
Detection antibody 
concentration 
LOD (pg/ml) 
IL-8 OptiBind™-E 2 µg/mL 0.16 µg/mL 1 
VEGF OptiBind™-F 2.5 µg/mL 0.05 µg/mL 2 (20 consecutive 
additions of 5 µl sample)   
hBD-1 OptiBind™-G 2 µg/mL 2 µg/mL 3  
TIMP-1 OptiBind™-E 1 µg/mL 1 µg/mL 3(5 consecutive 
additions of 5 µl sample)   
TIMP-2 OptiBind™-D 2 µg/mL 0.4 µg/mL 10(5 consecutive 
additions of 5 µl sample)   
 
A.3.2 Result  
All five protein markers were measurable in the spent medium, and average 
concentration is listed in table A1.2:  
Table A.2 Measured protein marker concentration from 16 EVPOME spent medium, 8 thermally stressed 
and 8 non-stressed 
Protein  
marker 
Tissue culture 
 condition 
Mean concentration 
 (pg/mL) 
SEM 
(pg/mL) 
P value 
IL-8 Control 16.5 4.3 0.04 
Thermally stressed 7.6 1.8 
hBD-1 Control 49.7 12.3 0.03 
Thermally stressed 20.3 8.2 
VEGF Control 24.1 6.9 0.07 
Thermally stressed 10.7 4.0 
TIMP-1 Control 75.9 26.0 0.15 
Thermally stressed 36.2 13.9 
TIMP-2 Control 168.4 28.4 0.02 
Thermally stressed 88.1 24.8 
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Among these protein markers, IL-8, hBD-1 and TIMP-2’s concentration was found to 
significantly correlate with the stress status of EVPOME tissue. The result has been 
published in Journal of Dental Research (2015, Vol 94, 78-84).  
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Appendix B  
 
Monolithic column fabrication for solid phase extraction of neuropeptides 
B.1 Objective 
To utilize monolithic column’s potential advantage in fast separation and low column 
back pressure for rapid neuropeptide preconcentration and detection. We selected 
polymer monolith to start because it is easier to synthesize than silica-based monolith, has 
better batch-to-batch reproducibility and can potentially achieve photo initiated 
polymerization to pattern the column for chip-based application. The polymer chosen was 
polystyrene-divinylbezene (PS-DVB), based on its high chemical inertness and excellent 
separation performance.  
B.2 Experiment 
B.2.1 Capillary vinylization 
The capillary inner wall needs to be vinylized in order to provide covalent bonding of 
monolith to the wall.  In brief, fused silica capillary was flushed with acetonitrile, water 
and filled by 1M NaOH solution. The capillary was sealed by septum and placed into 120℃ 
oven for 2 h to expose fresh silanol groups. The cleaned capillary was then washed with 
Mili-Q water till pH reached 7, flushed by acetone and allowed to dry in 120℃ for 1 h 
with nitrogen purging. After drying, vinylization mixture containing 50% (v/v) N, N-
dimethylformamide (DMF), 50% (v/v) 3-(trimethoxysilyl) propyl methacrylate, 0.01% 
w/v 2, 2-diphenyl-1-picrylhydrazyl was loaded into the capillary. Capillary was sealed 
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again and reacted under 120℃ for 6 h for completion of vinylization. The vinylized 
capillary was then washed by acetone and stored in the air till use. 
B.2.2 Polymerization 
The formation of a PS-DVB monolithic column is based on free radical 
polymerization of monomer styrene and cross-linker divinylbezene in a pore forming 
solvent (porogen). The morphology of the monolith is controlled by the porogen’s 
solvating power to the growing polymer chain, and poorer (more polar) solvents tend to 
have earlier phase separation which results in both larger nodule size and pore size. The 
polymerization mixture contained 1% w/v azobisisobutyronitrile (ratio to volume of 
monomers) and different compositions of monomer/cross-linker and monomer solvent 
(porogen) and is listed in Table B.1.  The mixture was filtered by 0.2 μm syringe filter 
(Whatman) and purged with nitrogen for 3 min to remove dissolved oxygen. Vinylized 
capillary was purged with N2 for 1h before loaded with mixture. The capillary was then 
immediately sealed and placed in a 70℃ circulating water bath for 24 h to form the 
monolith. After that, the monolithic columns were washed with MeOH to remove 
remaining monomers and dried by N2. Columns can be made in batch and stored for 2 
weeks prior to use.  
B.3 Result 
B.3.1 Formation of monolithic column and its preconcentration of ME at low 
injection flow rate 
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Figure B.1 Characterization of a PS-DVB column using microscopy and LC. (A) Environmental scanning 
electron microscope image of a monolithic column cross section. (B) HPLC separation of LE and ME on 
PS-DVB monolithic column. Column length: 5cm; column I.D.: 50 μm. Peptide was 500 nM in 1% HAc, 
injected volume was ~20 nL. Gradient: 0-0.1 min: 2-10% MPB, 0.1-6 min: 10% -50% MPB, 6-6.5 min:50% 
-95% MPB, 6.5- 7 min:95% MPB, 7-7.5 min: 95%-2% MPB. MPA: 1% HAc, MPB: 1% HAc in MeOH. 
(C) Peak area increased linearly as injection volume increased for 3nM ME in 0.5% HAc. Injection flow 
rate: 0.45 µL/min.  Column length: 5 cm; column I.D.: 50 μm; elution flow rate: 122 nL/min, elution 
solvent: 50%  MeOH with 1% HAc.  
 
  
6 8 10 12 14 
Time (min) 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 
100 
0 
100 
0 
100 
0 
(A) 
(B) 
0 5 10 15 20
0
1x10
8
2x10
8
3x10
8
M
E
 P
e
a
k
 A
re
a
Injection volume (L)
(C) 
TIC 
RIC LE 
RIC ME 
120 
 
B.3.2 LE signal decreases with increased injection flow rate 
 
Figure B.2 LE signal decreased as injection flow rate increased from 0.7 µL/min to 1 µL/min. 5 µL 1nM 
LE dissolved in aCSF was injected, and the injection time was kept at 20 min to allow additional loading 
solvent (water with 1% HAc) to rinse the column and remove the salt. Column length was 5 cm.  
B.3.3 Variation in polymerization mixture component to improve peptide retention 
Table B.1 Retention factor (k’) and backpressure of different materials derived from polystyrene-
divinylbenzene monolith. All columns were 50 μm I.D. column with 10 cm monolithic or packing bed. k’ 
was  measured using isocratic gradient of 20% MeOH with 2% HAc.  
Polymerization mixture compos ition and reference Applied pressure, 
flowrate 
k’ of ME 
column packed with 5 µm Alltima C18 particle 400 psi, 108 nl/min 16.02 
styrene: 200 µL,  divinylbenzene: 200 µL, 1- 
decanol: 520 µL, tetrahydrofuran: 80 µL
259
 
1120 psi,108 nl/min 1.11 
PS-DVB prepared as above and surface grafted with 
stearyl methacrylate
260
 
1020 psi, 104 nl/min 2.77 
styrene: 100 µL, octadecene: 100 µL, 
divinylbenzene: 200 µL, 1-decanol: 500 µL, DMF: 100 
µL
261
 
1000 psi, 108 nl/min 1.58 
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B.4 Discussion 
In this project PS-DVB column capable of retaining and separating enkephalins was 
fabricated. The column showed good capacity for concentrating ME when the peptide 
was injected at 0.45 µL/min (Figure B.1). Since the goal of this project was to fabricate 
monolithic column with low back pressure that could preconcentrate neuropeptides at 
elevated flow rate to improve analysis speed, I planned to test peptide signal under a 
range of injection flow rates. However as shown Figure B.2, slight increase of injection 
flow rate from 0.7 µL/min to 1 µL/min resulted in significant signal reduction of LE, the 
wide peak shape and shortened retention also indicated that at1 µL/min the column 
started to lose retention of LE. In addition, ME’s signal was totally lost at this flow rate, 
indicating the column started to lose retention of enkephalins when injection flow rate 
increased beyond 0.7 µL/min. Under this flow rate it could take ~20 min to inject and 
desalt 5 µL peptides, which did not fulfill the requirement of fast sample 
preconcentration. Altering monomer composition to incorporate C18 moiety was 
explored for increasing retention, however Table B.1 showed that the retention factor was 
not significantly enhanced, and was still ten times lower compared to that of a packed 
column. In the meantime, the back pressure of the monolithic columns was two times 
higher than that of a packed column with the same dimension. Further literature search 
has revealed that the claimed “low back pressure” of polymer monolithic column referred 
to their lower back pressure for achieving same protein separation performance compared 
to UPLC columns, which employs sub 2 µm packing. However the backpressure of such 
column is not absolutely lower compared to a standard LC column packed with 5 µm 
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particles
262
. Therefore, the polymer monolithic column was not applied to fast 
preconcentration of neuropeptides.  
Although PS-DVB monolithic column did not exhibit enough retention for rapid 
preconcentration of neuropeptides, the column may still be useful for extracting and 
separating molecules that are highly retained and not fully recovered on a packed C18 
column, such as proteins. In addition, as discussed in Chapter 5, silica monolithic column 
may be another promising extraction media for rapid neuropeptide preconcentration.   
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Appendix C  
 
 ELISA method for BDNF 
C.1 Objective 
To test ELISA kit’s sensitivity in detecting BDNF. I chose Promega BDNF Emax 
ImmunoAssay System because it claims to generate linear calibration curve within the 
range of 0.6 pM to 37 pM BDNF from 100 µL standard. In addition, this kit does not 
precoat wells with capture antibody therefore it offers more flexibility for method 
modification, eg. using 384 well plate instead of 96 well plate to reduce sample volume 
and improve mass sensitivity .  
C.2 Experiment 
ELISA was carried out according to vendor’s manual, except that 384 well Corning 
Costar plate (catalog number 3700) was used instead of a recommended 96 well plate of 
the same material, therefore 30 µL reagents and sample were used for maintaining same 
liquid height in the well. Also fluorescent detection was applied instead of absorbance 
because it was found to generate better linearity and sensitivity.  
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C.3 Result 
 
Figure C.1 BDNF calibration curve using Promega BDNF Emax ImmunoAssay System in a 384 well plate 
C.4 Discussion 
The LOD of this ELISA kit, calculated as blank signal +3×standard deviation of 
blank, was 1 pM, which was close to the value claimed in vendor’s manual. The mass 
LOD was 30 amol. However the curve reached plateau when BDNF concentration 
exceeded 5 pM, while the vendor’s manual claimed that the linear range should be 
extended to 37 pM.  The fluorescent signal was well below the saturation level of the 
plate reader. Possible source of the narrow linear range could be the capture antibody’s 
limited capacity to BDNF, therefore longer plate incubation and higher capture antibody 
concentration was tested, however the observation remained similar. In the meantime we 
started to develop highly sensitive signature peptide method for BDNF, and the method 
turned out to have similar mass LOD to the ELISA kit, therefore BDNF’s ELISA 
measurement was not continued.  
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Appendix D  
 
Supplemental Data for Chapter 3  
 
 
Figure D.1 Adding ACN to peptide sample increased orexin signal by reducing nonspecific adsorption to 
LC tubing. (A) Indication of peptide adsorption to LC tubing. Triplicate injection of 100 pM orexin A and 
orexin B in ringer solution, 0.5% FA, followed by 4 repeated injections of blank ringer solution containing 
0.5% FA, no ACN (0% ACN blank) and 1 injection of blank ringer solution containing 30% ACN and 0.5% 
FA (30% ACN blank). (B) Comparison of 100 pM orexins injected with 0% ACN and 25% ACN (3 
replicate injection for peptide standard) 1 blank injection after standard injection was also plotted.   
 
 
The peptides’ signal slowly decreased as number of 0% ACN blank injection 
increased. Orexin A’s signal disappeared after two 0% ACN blank injections, while 
orexin B’s signal was still observed in the fourth blank injection. The 30% ACN blank 
injection after four consecutive 0% ACN injection increased signal for both peptides: for 
orexin A it was higher than the standard injection and for orexin B the peak area was 80% 
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of the standard’s peak area. This indicated that the LC system was likely to have 
substantial contribution to adsorption loss.  
Carry-over for 0% ACN injection was 20% for orexin A and 60% for orexin B as 
estimated by peak area from the first blank injection after standard injection. When 
injected with 25% ACN the carry-over was 0.7 % and 2% for orexin A and orexin B, 
respectively.  
 
 
Figure D.2  Correlation between peptide size and charge to probe recovery. (A) Correlation between 
peptide net charge and improvement of relative recovery when using PEI modified probe; (B) correlation 
between peptide net charge at pH 7.4 and relative recovery of both PEI modified probe and unmodified 
probe; (C) correlation between peptide molecular weight and improvement of relative recovery when using 
PEI modified probe; (D) correlation between peptide molecular weight and relative recovery of both PEI 
modified probe and unmodified probe. 
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